aspirin and Antiphospholipid Syndrome studies

Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.

Antiphospholipid Syndrome: The presence of antibodies directed against phospholipids (ANTIBODIES, ANTIPHOSPHOLIPID). The condition is associated with a variety of diseases, notably systemic lupus erythematosus and other connective tissue diseases, thrombopenia, and arterial or venous thromboses. In pregnancy it can cause abortion. Of the phospholipids, the cardiolipins show markedly elevated levels of anticardiolipin antibodies (ANTIBODIES, ANTICARDIOLIPIN). Present also are high levels of lupus anticoagulant (LUPUS COAGULATION INHIBITOR).

Research Excerpts

Excerpt	Relevance	Reference
"To examine whether combined treatment with low-molecular-weight heparin (LMWH) and aspirin reduces recurrent hypertensive disorders of pregnancy (HD: pre-eclampsia, eclampsia or HELLP syndrome) in women with antiphospholipid antibodies (aPLA) and a previous delivery for HD and/or small-for-gestational-age (SGA) birthweight before 34 weeks gestation."	9.22	Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. ( Bezemer, D; de Vries, JI; Hague, WM; van Hoorn, ME; van Pampus, MG, 2016)
"To compare live birth rates in women with recurrent pregnancy loss (RPL) and either autoantibodies or a coagulation abnormality, treated with low molecular weight heparin plus aspirin (LMWH/ASA) or ASA alone, and to place our results in context with other randomized clinical trials (RCT) with similar cohorts."	9.14	Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. ( Barrett, J; Clark, CA; Crowther, MR; Gent, M; Ginsberg, JS; Hawker, GA; Kingdom, JC; Laskin, CA; Spitzer, KA, 2009)
" Major hemorrhages were observed more frequently in the combination (warfarin plus low-dose aspirin) therapy group than in the warfarin monotherapy group."	9.14	[Recurrent thromboses and hemorrhagic complications in patients with antiphospholipid syndrome during therapy with warfarin plus aspirin]. ( Aleksandrova, EN; Kondrat'eva, LV; Kovalenko, TF; Ostriakova, EV; Patrushev, LI; Patrusheva, NL; Reshetniak, TM, 2010)
"Aspirin combined with LMWH for APS may improve live birth rate, and detection of d-dimer levels in APS pregnant women may predict pregnancy complications and guide the use of anticoagulants."	9.12	Meta-analysis on aspirin combined with low-molecular-weight heparin for improving the live birth rate in patients with antiphospholipid syndrome and its correlation with d-dimer levels. ( Diao, QZ; Gu, ZD; Shi, T, 2021)
"Aspirin desensitization may be a safe alternative even during pregnancy if carefully monitored and permit patients with APS to receive treatment with ASA."	9.12	Aspirin desensitization in the treatment of antiphospholipid syndrome during pregnancy in ASA-sensitive patients. ( Alijotas-Reig, J; Cisteró-Bahíma, A; San Miguel-Moncín, M, 2006)
"To determine the efficacy of a daily dose of 81 mg aspirin in primary thrombosis prevention in asymptomatic, persistently antiphospholipid antibody (aPL)-positive individuals (those with positive aPL but no vascular and/or pregnancy events)."	9.12	Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. ( Erkan, D; Harrison, MJ; Levy, R; Lockshin, MD; Peterson, M; Petri, M; Sammaritano, L; Unalp-Arida, A; Vilela, V; Yazici, Y, 2007)
"To assess efficacy and safety of warfarin therapy and its combination with low-dose acetylsalicylic acid (ASA) in antiphospholipid syndrome (APS)."	9.12	[Warfarin in the treatment of antiphospholipid syndrome]. ( Kondrat'eva, LV; Patrushev, LI; Patrusheva, NL; Reshetniak, TM, 2007)
"0 in 52 patients or aspirin alone, 100 mg day(-1) in three patients) to determine whether intensive anticoagulation is superior to standard treatment in preventing symptomatic thromboembolism without increasing the bleeding risk."	9.11	A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). ( Barbui, T; Baudo, F; Berrettini, M; Brancaccio, V; D'Angelo, A; Finazzi, G; Marchioli, R; Musial, J; Schinco, P; Testa, S; Tognoni, G; Wisloff, F, 2005)
" Aspirin (75 mg daily) was commenced at the time of a positive pregnancy test and heparin (5000 units subcutaneously 12 hourly, or enoxaparin 20 mg daily) was started when fetal heart activity was demonstrated on ultrasound."	9.09	Pregnancy complications in women with recurrent miscarriage associated with antiphospholipid antibodies treated with low dose aspirin and heparin. ( Backos, M; Baxter, N; Chilcott, IT; Cohen, H; Rai, R; Regan, L, 1999)
"This preliminary study suggests that low-dose aspirin has no additional benefit when added to supportive care for women for whom recurrent early fetal loss is the only sequela of the antiphospholipid syndrome."	9.09	Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial. ( Birdsall, M; Chamley, LW; Liddell, HS; McDougall, J; Pattison, NS; Zanderigo, AM, 2000)
"Heparin plus low-dose aspirin provides a significantly better pregnancy outcome than low-dose aspirin alone does for antiphospholipid antibody-associated recurrent pregnancy loss."	9.08	Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. ( Kutteh, WH, 1996)
"An improvement of pregnancy outcomes in women with RSA and APS can be achieved by treatment strategies combining low-dose aspirin plus heparin or heparin alone."	9.01	Aspirin or heparin or both in the treatment of recurrent spontaneous abortion in women with antiphospholipid antibody syndrome: a meta-analysis of randomized controlled trials. ( Jiang, HL; Liu, Y; Lu, C, 2019)
"The use of low-dose aspirin and heparinoids has improved the pregnancy outcome in obstetric antiphospholipid syndrome (APS)."	8.93	The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Evidence and clinical judgment. ( Branch, DW; Hunt, BJ; Khamashta, M; Levy, RA; Middeldorp, S; Pavord, S; Roccatello, D; Ruiz-Irastorza, G; Schreiber, K; Sciascia, S; Tincani, A, 2016)
"We performed a meta-analysis to determine whether aspirin has a significant protective effect on risk of first thrombosis among patients with antiphospholipid antibodies (aPL+)."	8.90	Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. ( Amoura, Z; Arnaud, L; Balasch, J; Cervera, R; Erkan, D; Forastiero, R; Lambert, M; Martinez-Zamora, MA; Mathian, A; Pengo, V; Ruffatti, A; Tektonidou, M; Wahl, D; Zuily, S, 2014)
"To evaluate the efficacy and safety of anticoagulant agents, such as aspirin and heparin, in women with a history of at least two unexplained miscarriages with or without inherited thrombophilia."	8.90	Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia. ( de Jong, PG; Di Nisio, M; Goddijn, M; Kaandorp, S; Middeldorp, S, 2014)
"The combination of heparin and aspirin was regarded as the 'standard therapy' for patients with recurrent pregnancy loss (RPL) and positive aPL antibodies to enhance live births, but it largely stems from expert opinion."	8.86	Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression. ( Cheak, AA; Cheung, MW; Ho, RC; Mak, A, 2010)
"To evaluate the efficacy and safety of anticoagulant agents, such as aspirin and heparin, in women with a history of at least two miscarriages without apparent causes other than inherited thrombophilia."	8.85	Aspirin or anticoagulants for treating recurrent miscarriage in women without antiphospholipid syndrome. ( Di Nisio, M; Goddijn, M; Kaandorp, S; Middeldorp, S, 2009)
" In patients with arterial or venous thrombosis, there is a high rate of recurrence during the two first years except if high-dose warfarin was used (i."	8.80	[Aspirin and antiphospholipid syndrome]. ( Blétry, O; Hachulla, E; Hatron, PY; Piette, AM, 2000)
"The current treatment to prevent pregnancy morbidity (PM) associated with antiphospholipid antibodies (aPL) is based on the use of low dose aspirin and low molecular weight heparin (henceforth defined as standard of care (SoC) treatment)."	7.96	Pregnancy success rate and response to heparins and/or aspirin differ in women with antiphospholipid antibodies according to their Global AntiphosPholipid Syndrome Score. ( Cecchi, I; Cuadrado, MJ; Radin, M; Roccatello, D; Rubini, E; Schreiber, K; Sciascia, S, 2020)
"A previous pilot study showed that pravastatin supplementation improved pregnancy outcomes in women with obstetric antiphospholipid syndrome (OAPS) that developed placental insufficiency despite standard of care treatment low molecular weight heparin plus low dose aspirin (LMWH + LDA)."	7.96	Triple therapy with pravastatin, low molecular weight heparin and low dose aspirin improves placental haemodynamics and pregnancy outcomes in obstetric antiphospholipid syndrome in mice and women through a nitric oxide-dependent mechanism. ( Contento, G; Girardi, G; Jurisic, A; Jurisic, Z; Lefkou, E; Pombo, J; Varoudi, K, 2020)
"The objective of this study was to assess pregnancy outcome in women with a history of refractory antiphospholipid antibody-associated pregnancy loss(es) who were treated with early low-dose prednisolone in addition to aspirin and heparin."	7.77	First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss. ( Bramham, K; Hunt, BJ; Khamashta, M; Nelson-Piercy, C; Thomas, M, 2011)
"9 years) with confirmed diagnoses of cerebral infarction and PAS, treated with anticoagulants (n = 54) or aspirin (n = 38) were retrospectively analyzed."	7.77	[Aspirin versus anticoagulation in young patients with cerebral infarction secondary to primary antiphospholipid syndrome]. ( Arauz, A; Artigas, C; Barinagarrementeria, F; Cantu-Brito, C; Hernandez, B; Marquez, JM; Merlos, M; Perez, A; Roa, LF, 2011)
"The aim of this retrospective, observational study was to determine the impact of low-dose enoxaparin (20 mg) in conjunction with low-dose aspirin on the pregnancy outcome of women with antiphospholipid syndrome and recurrent miscarriage."	7.75	Treatment of recurrent miscarriage and antiphospholipid syndrome with low-dose enoxaparin and aspirin. ( Li, TC; Makris, M; Metwally, M; Mo, D; Saravelos, S, 2009)
" During pregnancy, aspirin prophylaxis was prescribed and followed by steroids after caesarian section."	7.73	[Acute myocardial infarction complicating primary antiphospholipid syndrome after aspirin and steroids withdrawal]. ( Galicier, L; Guillevin, L; Meune, C; Salengro, E; Spaulding, C; Wahbi, K; Weber, S, 2005)
"The authors describe course and outcome of eight patients with ischemic stroke as the first thrombotic manifestation of antiphospholipid syndrome who received low-dose aspirin as prophylactic treatment."	7.72	Low dose aspirin after ischemic stroke associated with antiphospholipid syndrome. ( de Groot, PG; Derksen, RH; Kappelle, LJ, 2003)
"To evaluate the effect of aspirin treatment upon fetal loss in mice with experimental antiphospholipid syndrome (APLS)."	7.68	The effect of aspirin on recurrent fetal loss in experimental antiphospholipid syndrome. ( Blank, M; Gilbrut, B; Krause, I; Shoenfeld, Y, 1993)
"Treatment with prednisone and aspirin appears to be efficacious, safe, and economic in the prevention of pregnancy loss and fetal growth retardation in patients with aCL."	7.68	Prevention of anticardiolipin antibody-related pregnancy losses with prednisone and aspirin. ( Angel, J; Espinoza, LR; Hubble, CL; Jara, LJ; Martínez-Osuna, P; O'Brien, W; Saway, S; Seleznick, MJ; Silveira, LH, 1992)
"Hydroxychloroquine (HCQ) is an immunomodulatory agent that has been shown in laboratory studies to decrease thrombosis risk, support placentation, and minimize the destructive effects of antiphospholipid antibodies."	7.01	Does adding hydroxychloroquine to empiric treatment improve the live birth rate in refractory obstetrical antiphospholipid syndrome? A systematic review. ( Bacal, V; Bedaiwy, MA; Hooper, A, 2023)
"Treatment with prednisolone (7."	5.30	[A case of antiphospholipid antibody syndrome successfully treated with prednisolone and low-dose aspirin, with subsequent normal pregnancy]. ( Maeda, T; Maesima, E; Yamada, Y; Yamamoto, M; Yukawa, S, 1997)
"Aspirin acts as a potent stimulator of IL-3 through its ability to raise leukotriene production, which induces production of IL-3 both in vitro and in vivo."	5.29	Aspirin modulates interleukin-3 production: additional explanation for the preventive effects of aspirin in antiphospholipid antibody syndrome. ( Falach-Vaknin, E; Fishman, P; Meroni, PL; Rudniki, C; Shoenfeld, Y; Sredni, B, 1995)
"To examine whether combined treatment with low-molecular-weight heparin (LMWH) and aspirin reduces recurrent hypertensive disorders of pregnancy (HD: pre-eclampsia, eclampsia or HELLP syndrome) in women with antiphospholipid antibodies (aPLA) and a previous delivery for HD and/or small-for-gestational-age (SGA) birthweight before 34 weeks gestation."	5.22	Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. ( Bezemer, D; de Vries, JI; Hague, WM; van Hoorn, ME; van Pampus, MG, 2016)
"The objectives of this study are to examine the efficacy and safety of low-dose aspirin (LDA) vs LDA plus low-intensity warfarin (LDA + W) in the primary thrombosis prevention of aPL-positive patients with SLE and/or obstetric morbidity and the role of clinical and serological markers in the development of thrombosis."	5.19	Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS). ( Aguirre, A; Akil, M; Amigo, MC; Bertolaccini, ML; Cuadrado, MJ; Egurbide, MV; Espinosa, G; Galindo, M; Gil, A; Gordon, C; Houssiau, F; Khamashta, MA; Martin, H; McHugh, N; Mico, L; Murru, V; Rahman, A; Ruiz-Irastorza, G; Seed, PT; Tektonidou, MG, 2014)
"To determine whether low molecular weight heparin (LMWH) plus low-dose aspirin (LDA) is comparable in efficacy and safety to unfractionated heparin (UFH) plus LDA in the management of pregnant women with a history of recurrent spontaneous abortion secondary to antiphospholipid syndrome (APS)."	5.15	Enoxaparin versus unfractionated heparin in the management of recurrent abortion secondary to antiphospholipid syndrome. ( Abdou, AM; Fouda, IM; Fouda, UM; Ramadan, DI; Sayed, AM; Zaki, MM, 2011)
"To compare live birth rates in women with recurrent pregnancy loss (RPL) and either autoantibodies or a coagulation abnormality, treated with low molecular weight heparin plus aspirin (LMWH/ASA) or ASA alone, and to place our results in context with other randomized clinical trials (RCT) with similar cohorts."	5.14	Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. ( Barrett, J; Clark, CA; Crowther, MR; Gent, M; Ginsberg, JS; Hawker, GA; Kingdom, JC; Laskin, CA; Spitzer, KA, 2009)
" Major hemorrhages were observed more frequently in the combination (warfarin plus low-dose aspirin) therapy group than in the warfarin monotherapy group."	5.14	[Recurrent thromboses and hemorrhagic complications in patients with antiphospholipid syndrome during therapy with warfarin plus aspirin]. ( Aleksandrova, EN; Kondrat'eva, LV; Kovalenko, TF; Ostriakova, EV; Patrushev, LI; Patrusheva, NL; Reshetniak, TM, 2010)
"The most efficacious strategy to manage pregnant patients with antiphospholipid syndrome (APS) refractory to conventional heparin/low-dose aspirin treatment or at high risk of adverse pregnancy outcomes has not been determined with any degree of certainty."	5.12	The efficacy and safety of second-line treatments of refractory and/or high risk pregnant antiphospholipid syndrome patients. A systematic literature review analyzing 313 pregnancies. ( Calligaro, A; Del Ross, T; Favaro, M; Gervasi, MT; Hoxha, A; Ruffatti, A; Ruffatti, AT; Tonello, M, 2021)
"Aspirin combined with LMWH for APS may improve live birth rate, and detection of d-dimer levels in APS pregnant women may predict pregnancy complications and guide the use of anticoagulants."	5.12	Meta-analysis on aspirin combined with low-molecular-weight heparin for improving the live birth rate in patients with antiphospholipid syndrome and its correlation with d-dimer levels. ( Diao, QZ; Gu, ZD; Shi, T, 2021)
"This was a prospective clinical trial conducted at Khartoum Fertility Center, during the period June 2002 to February 2005 to investigate the efficacy of unfractionated heparin and low-dose aspirin as prophylaxis against pregnancy loss in 58 pregnant Sudanese women with recurrent (> or = 3) miscarriages associated with antiphospholipid syndrome (APS)."	5.12	Heparin and aspirin in pregnant Sudanese women with recurrent miscarriage associated with antiphospholipid antibodies. ( A/Magid, YM; A/Rahim, F; Adam, I; Elussein, EA; Omer, MM; Samaan, SI, 2007)
"Aspirin desensitization may be a safe alternative even during pregnancy if carefully monitored and permit patients with APS to receive treatment with ASA."	5.12	Aspirin desensitization in the treatment of antiphospholipid syndrome during pregnancy in ASA-sensitive patients. ( Alijotas-Reig, J; Cisteró-Bahíma, A; San Miguel-Moncín, M, 2006)
"To examine whether there were any differences in the endocrinological profiles during conception cycle and early pregnancy between a control group and women with a history of recurrent miscarriage that was caused by antiphospholipid syndrome and that was treated with aspirin and low molecular weight heparin."	5.12	Preliminary prospective study of the endocrinology of conception cycles and early pregnancy in women with antiphospholipid syndrome treated with low molecular weight heparin. ( Laird, S; Ledger, WL; Li, TC; Prakash, A, 2006)
"To determine the efficacy of a daily dose of 81 mg aspirin in primary thrombosis prevention in asymptomatic, persistently antiphospholipid antibody (aPL)-positive individuals (those with positive aPL but no vascular and/or pregnancy events)."	5.12	Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. ( Erkan, D; Harrison, MJ; Levy, R; Lockshin, MD; Peterson, M; Petri, M; Sammaritano, L; Unalp-Arida, A; Vilela, V; Yazici, Y, 2007)
"To assess efficacy and safety of warfarin therapy and its combination with low-dose acetylsalicylic acid (ASA) in antiphospholipid syndrome (APS)."	5.12	[Warfarin in the treatment of antiphospholipid syndrome]. ( Kondrat'eva, LV; Patrushev, LI; Patrusheva, NL; Reshetniak, TM, 2007)
"To compare low molecular weight heparin (LMWH), specifically dalteparin, to unfractionated heparin (UFH) for the treatment of antiphospholipid antibody syndrome (APS) in pregnancy."	5.11	Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin. ( Ballem, PJ; Ensom, MH; Ensworth, S; Houlihan, E; Purkiss, S; Stephenson, MD; Tsang, P, 2004)
"The aim of this study was to evaluate the effects of two different prophylactic protocols, low-dose aspirin and fish oil derivates, in the treatment of patients with recurrent pregnancy loss associated with antiphospholipid antibodies (APA) syndrome."	5.11	Recurrent miscarriage associated with antiphospholipid antibodies: prophylactic treatment with low-dose aspirin and fish oil derivates. ( Carta, G; Falciglia, K; Iovenitti, P, 2005)
"0 in 52 patients or aspirin alone, 100 mg day(-1) in three patients) to determine whether intensive anticoagulation is superior to standard treatment in preventing symptomatic thromboembolism without increasing the bleeding risk."	5.11	A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). ( Barbui, T; Baudo, F; Berrettini, M; Brancaccio, V; D'Angelo, A; Finazzi, G; Marchioli, R; Musial, J; Schinco, P; Testa, S; Tognoni, G; Wisloff, F, 2005)
"05) in pregnancy outcomes between the two studied therapeutic protocols, but the therapy with aspirin and low-molecular heparin was cheaper and easier to apply than the therapy with immunoglobulins."	5.11	Comparison of two therapeutic protocols in patients with antiphospholipid antibodies and recurrent miscarriages. ( Dukanac, J; Gojnić, M; Jeremić, K; Ljubić, A; Pervulov, M; Stojnić, J, 2005)
"To compare the efficacy of low-dose aspirin alone versus low-dose aspirin plus low molecular weight heparin in pregnant women with antiphospholipid syndrome and recurrent miscarriage as prophylaxis against pregnancy loss."	5.10	Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. ( Farquharson, RG; Greaves, M; Quenby, S, 2002)
"To compare the 2 most efficacious therapeutic regimens, intravenous immunoglobulin (IVIG) and anticoagulation with low molecular weight (LMW) heparin plus low-dose aspirin, in women with recurrent pregnancy loss associated with antiphospholipid antibodies (aPL)."	5.10	Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. ( Accardo-Palumbo, A; Castelli, A; Ciccia, F; Ferrante, A; Giarratano, A; Licata, G; Perino, A; Triolo, G, 2003)
" Aspirin (75 mg daily) was commenced at the time of a positive pregnancy test and heparin (5000 units subcutaneously 12 hourly, or enoxaparin 20 mg daily) was started when fetal heart activity was demonstrated on ultrasound."	5.09	Pregnancy complications in women with recurrent miscarriage associated with antiphospholipid antibodies treated with low dose aspirin and heparin. ( Backos, M; Baxter, N; Chilcott, IT; Cohen, H; Rai, R; Regan, L, 1999)
"This preliminary study suggests that low-dose aspirin has no additional benefit when added to supportive care for women for whom recurrent early fetal loss is the only sequela of the antiphospholipid syndrome."	5.09	Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial. ( Birdsall, M; Chamley, LW; Liddell, HS; McDougall, J; Pattison, NS; Zanderigo, AM, 2000)
"Heparin plus low-dose aspirin provides a significantly better pregnancy outcome than low-dose aspirin alone does for antiphospholipid antibody-associated recurrent pregnancy loss."	5.08	Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. ( Kutteh, WH, 1996)
"We compared the use of aspirin alone with combined therapy (prednisone plus aspirin) in antiphospholipid antibody-positive obstetric patients with prior adverse pregnancy outcome."	5.07	Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients. ( Hobart, JM; MacGregor, SN; Neerhof, MG; Ragin, A; Sholl, JS; Silver, RK, 1993)
"An improvement of pregnancy outcomes in women with RSA and APS can be achieved by treatment strategies combining low-dose aspirin plus heparin or heparin alone."	5.01	Aspirin or heparin or both in the treatment of recurrent spontaneous abortion in women with antiphospholipid antibody syndrome: a meta-analysis of randomized controlled trials. ( Jiang, HL; Liu, Y; Lu, C, 2019)
" We analyzed the outcome of pregnancies in patients with obstetrical APS (Sydney criteria) and previous adverse obstetrical event despite low-dose aspirin and low-molecular weight heparin LMWH (LMWH) conventional treatment who experienced at least one subsequent pregnancy."	4.95	Refractory obstetrical antiphospholipid syndrome: Features, treatment and outcome in a European multicenter retrospective study. ( Abisror, N; Alijotas-Reig, J; Andreoli, L; Carrat, F; Costedoat-Chalumeau, N; De Carolis, S; Esteve-Valverde, EE; Fain, O; Ferrer-Oliveras, R; Josselin-Mahr, L; Lazzaroni, MG; Maina, A; Masseau, A; Mekinian, A; Morel, N; Nicaise-Roland, P; Ruffatti, A; Tabacco, S; Tincani, A, 2017)
"The use of aspirin and heparin has improved the pregnancy outcome in obstetric APS and approximately 70% of pregnant women with APS have a successful pregnancy outcome."	4.95	Current insights in obstetric antiphospholipid syndrome. ( Radin, M; Schreiber, K; Sciascia, S, 2017)
"The use of low-dose aspirin and heparinoids has improved the pregnancy outcome in obstetric antiphospholipid syndrome (APS)."	4.93	The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Evidence and clinical judgment. ( Branch, DW; Hunt, BJ; Khamashta, M; Levy, RA; Middeldorp, S; Pavord, S; Roccatello, D; Ruiz-Irastorza, G; Schreiber, K; Sciascia, S; Tincani, A, 2016)
" Although current treatment regimens including aspirin and low-molecular weight heparin have improved pregnancy outcomes, 30% of affected women have pregnancy complica-tions."	4.93	[Antiphospholipid syndrome and pregnancy]. ( Jacobsen, S; Langhoff-Roos, J; Lykke, JA; Nielsen, HS; Schreiber, K, 2016)
"We performed a meta-analysis to determine whether aspirin has a significant protective effect on risk of first thrombosis among patients with antiphospholipid antibodies (aPL+)."	4.90	Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. ( Amoura, Z; Arnaud, L; Balasch, J; Cervera, R; Erkan, D; Forastiero, R; Lambert, M; Martinez-Zamora, MA; Mathian, A; Pengo, V; Ruffatti, A; Tektonidou, M; Wahl, D; Zuily, S, 2014)
" Current treatment of patients with antiphospholipid syndrome (APS) during pregnancy with heparin and aspirin can act by preventing clot formation and improving live birth rates, but other obstetric morbidities remain high, especially in patients with a history of thrombotic events."	4.90	Pregnancy morbidity in antiphospholipid syndrome: what is the impact of treatment? ( de Jesús, GR; de Jesús, NR; Levy, RA; Rodrigues, G, 2014)
"To evaluate the efficacy and safety of anticoagulant agents, such as aspirin and heparin, in women with a history of at least two unexplained miscarriages with or without inherited thrombophilia."	4.90	Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia. ( de Jong, PG; Di Nisio, M; Goddijn, M; Kaandorp, S; Middeldorp, S, 2014)
"The combination of heparin and aspirin was regarded as the 'standard therapy' for patients with recurrent pregnancy loss (RPL) and positive aPL antibodies to enhance live births, but it largely stems from expert opinion."	4.86	Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression. ( Cheak, AA; Cheung, MW; Ho, RC; Mak, A, 2010)
"To estimate the effect of combined heparin and aspirin compared with aspirin monotherapy in pregnant women with antiphospholipid syndrome and recurrent pregnancy loss."	4.86	Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: a systematic review and meta-analysis. ( Pavlou, M; Voulgarelis, M; Ziakas, PD, 2010)
"To evaluate the efficacy and safety of anticoagulant agents, such as aspirin and heparin, in women with a history of at least two miscarriages without apparent causes other than inherited thrombophilia."	4.85	Aspirin or anticoagulants for treating recurrent miscarriage in women without antiphospholipid syndrome. ( Di Nisio, M; Goddijn, M; Kaandorp, S; Middeldorp, S, 2009)
" Low dose aspirin should be given to every pregnant woman with antiphospholipid antibodies, with the addition of low molecular weight heparin in those with previous thrombosis, previous fetal death or failure of monotherapy with aspirin."	4.85	[The antiphospholipid syndrome in the 21st century]. ( Egurbide, MV; Martinez-Berriotxoa, A; Ruiz-Irastorza, G, 2009)
" first venous thrombosis) should be treated with warfarin to an INR 2."	4.85	Management of antiphospholipid syndrome. ( Khamashta, MA; Tuthill, JI, 2009)
" Clinical trials have demonstrated that patients with antiphospholipid antibodies and venous thromboembolism should be treated with vitamin K antagonists (warfarin); that ischemic stroke may be treated with aspirin or warfarin; and that women with recurrent pregnancy loss should receive prophylactic-dose heparin and aspirin."	4.85	Antiphospholipid antibody syndrome. ( Lim, W, 2009)
" Combined aspirin and heparin for antiphospholipid syndrome, and screening and treatment of bacterial vaginosis between ten and 22 weeks of pregnancy with clindamycin, are the only interventions proven to be useful in randomised controlled trials (RCTs)."	4.84	Non-surgical interventions for threatened and recurrent miscarriages. ( Tan, TY; Tien, JC, 2007)
"Although intra-uterine fetal death is considered at high risk of recurrence in case of antiphospholipid syndrome (APS), a uniform management protocol including aspirin and heparin and close obstetrical follow-up led to a favorable outcome in most cases."	4.82	Antiphospholipid syndrome and second- or third-trimester fetal death: follow-up in the next pregnancy. ( Bats, AS; Carbonne, B; Cynober, E; Gonzales, M; Lejeune, V; Milliez, J; Safar, E, 2004)
" The management of pregnant patients with antiphospholipid syndrome is mainly based on the use of antiaggregant/anticoagulant agents (with aspirin and heparin) to prevent thrombosis in the uteroplacental circulation."	4.82	The management of pregnant patients with antiphospholipid syndrome. ( Balasch, J; Cervera, R, 2004)
" The recurrent pregnancy loss that is associated with this disease is managed with prophylactic low dose aspirin and heparin therapy."	4.82	Immunologic manipulation for the threatened fetus. ( Benson, EM, 2004)
" Aspirin, prednisone and heparin are most commonly utilized but are not clearly proven to outperform expectant management except in case of antiphospholipid syndrome."	4.81	[Medical treatment for recurrent miscarriages]. ( Belaisch-Allart, J; Mayenga, JM, 2002)
"Combination therapy with aspirin and heparin may reduce pregnancy loss in women with antiphospholipid antibodies by 54%."	4.81	Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of therapeutic trials. ( Craig, JC; Empson, M; Lassere, M; Scott, JR, 2002)
" The combination of heparin and low-dose aspirin is effective in significantly increasing the chances of a successful pregnancy in woman with recurrent pregnancy failure associated with antiphospholipid antibodies."	4.81	Treatment of the antiphospholipid syndrome. ( Roubey, RA, 2002)
" In patients with arterial or venous thrombosis, there is a high rate of recurrence during the two first years except if high-dose warfarin was used (i."	4.80	[Aspirin and antiphospholipid syndrome]. ( Blétry, O; Hachulla, E; Hatron, PY; Piette, AM, 2000)
" Hence, in several patient series the use of IVIg either solely or in combination with aspirin/heparin resulted in successful pregnancy outcome in the vast majority of APS patients with recurrent abortions."	4.80	Intravenous immunoglobulin therapy of antiphospholipid syndrome. ( Levy, Y; Sherer, Y; Shoenfeld, Y, 2000)
" It seems effective for the prevention of recurrent pregnancy losses when conventional strategies using subcutaneous heparin and low-dose aspirin have failed."	4.80	[Therapeutic use of intravenous immunoglobulins in the antiphospholipid syndrome]. ( Lê Thi Huong, D; Piette, JC; Wechsler, B, 2000)
"The gold standard for treatment of the antiphospholipid antibody syndrome (APS) after thrombosis remains high-intensity warfarin, and, in pregnancy, heparin and aspirin."	4.80	Treatment of the antiphospholipid antibody syndrome: progress in the last five years? ( Petri, M, 2000)
" In this context, the effectiveness of the new direct oral anticoagulants in antiphospholipid syndrome is debated, as well as that of low-dose aspirin for primary thromboprophylaxis."	4.31	Controversies in the Management of Antiphospholipid Syndrome. ( Alba Moreyra, P; de Andrade, DCO; Erkan, D; Gómez-Puerta, JA; Jara, LJ; Pons-Estel, GJ; Porta, SV, 2023)
"(1) To assess the clinical utility of the adjusted global antiphospholipid syndrome score (aGAPSS) to predict new obstetric events during follow-up in primary obstetric antiphospholipid syndrome (POAPS) patients under standard-of-care treatment (SC) based on the use of low-dose aspirin (LDA) + heparin and (2) to study the risk of a first thrombotic event and to evaluate whether stratification according to this score could help to identify POAPS patients who would benefit from long-term thromboprophylaxis."	4.12	Clinical and therapeutic value of the adjusted Global Antiphospholipid Syndrome Score in primary obstetric antiphospholipid syndrome. ( Alijotas-Reig, J; Aranda, F; Belizna, C; de Larrañaga, G; Esteve-Valverde, E; Fernández-Romero, DS; Latino, JO; Peréz, SM; Udry, S; Wingeyer, SP, 2022)
"5%) with a history of pregnancy morbidity alone were treated with prophylactic low molecular weight heparin (LMWH) + low-dose aspirin (LDA, 100 mg) (group I) and 40 (31."	3.96	Upgrading Therapy Strategy Improves Pregnancy Outcome in Antiphospholipid Syndrome: A Cohort Management Study. ( Calligaro, A; Del Ross, T; Favaro, M; Hoxha, A; Infantolino, C; Mattia, E; Ruffatti, A; Ruffatti, AT; Tonello, M, 2020)
"The current treatment to prevent pregnancy morbidity (PM) associated with antiphospholipid antibodies (aPL) is based on the use of low dose aspirin and low molecular weight heparin (henceforth defined as standard of care (SoC) treatment)."	3.96	Pregnancy success rate and response to heparins and/or aspirin differ in women with antiphospholipid antibodies according to their Global AntiphosPholipid Syndrome Score. ( Cecchi, I; Cuadrado, MJ; Radin, M; Roccatello, D; Rubini, E; Schreiber, K; Sciascia, S, 2020)
" These patients were grouped into three groups according to their treatment plan including those who received low dose aspirin (LDA) alone (group A), LDA plus LMWH after ovulation therapy (group B), and LDA plus LMWH after pregnancy confirmation (group C)."	3.96	D-Dimer Assay May Guide LMWH Treatment in Repeated Biochemical Pregnancy Losses in Women with Positive Antiphospholipid Antibody. ( Bao, SH; Frempong, ST; Ruan, JL, 2020)
"A previous pilot study showed that pravastatin supplementation improved pregnancy outcomes in women with obstetric antiphospholipid syndrome (OAPS) that developed placental insufficiency despite standard of care treatment low molecular weight heparin plus low dose aspirin (LMWH + LDA)."	3.96	Triple therapy with pravastatin, low molecular weight heparin and low dose aspirin improves placental haemodynamics and pregnancy outcomes in obstetric antiphospholipid syndrome in mice and women through a nitric oxide-dependent mechanism. ( Contento, G; Girardi, G; Jurisic, A; Jurisic, Z; Lefkou, E; Pombo, J; Varoudi, K, 2020)
"Women with antiphospholipid antibodies (aPL) are at risk for pregnancy complications despite treatment with low molecular weight heparin (LMWH) or aspirin (ASA)."	3.88	Low molecular weight heparin and aspirin exacerbate human endometrial endothelial cell responses to antiphospholipid antibodies. ( Abrahams, VM; Bryce, E; Chamley, LW; Guller, S; Quao, ZC; Tong, M, 2018)
"The use of low-dose aspirin in pregnancy should remain a highly targeted indication since its long-term safety has not been established and should be restricted to women at high risk of vascular complications."	3.85	[For a targeted use of aspirin]. ( Brun, S; Coatleven, F; Gleyze, M; Lecoq, C; Madar, H; Merlot, B; Nithart, A; Sentilhes, L, 2017)
" Main causes of oral anticoagulant treatment cessation were switch from vitamin K antagonists to aspirin in 15 patients, prolonged disappearance of antiphospholipid antibodies in ten, bleeding complications in nine and a poor therapeutic adherence in six."	3.85	Cessation of oral anticoagulants in antiphospholipid syndrome. ( Cacoub, P; Castel, B; Comarmond, C; de Menthon, M; Decaux, O; Elmaleh-Sachs, A; Ferreira-Maldent, N; Fraisse, T; Goujard, C; Hyvernat, H; Jego, P; Khau, D; Leroux, G; Marie, I; Mekinian, A; Michon, A; Monnier, S; Nguen, Y; Oziol, E; Piette, JC; Saadoun, D; Sarrot-Reynauld, F; Thiercein-Legrand, MF; Veyssier-Belot, C, 2017)
" Risk factors for pregnancy complications, including premature delivery before 34 gestational weeks, hypertensive disorders of pregnancy, thrombocytopenia, and light-for-date neonate, were evaluated in 51 women who received low dose aspirin (LDA) plus unfractionated heparin (UFH) and delivered after 24 GW."	3.85	Factors associated with adverse pregnancy outcomes in women with antiphospholipid syndrome: A multicenter study. ( Deguchi, M; Fujita, D; Makino, S; Miki, A; Morikawa, M; Murashima, A; Sugiura-Ogasawara, M; Yamada, H, 2017)
"The management of patients with recurrent miscarriage (RM) and antiphospholipid antibody syndrome (APS) includes prolonged treatment with heparin and aspirin, starting from the confirmation of pregnancy and continuing until 6 weeks after birth."	3.85	Antiphospholipid Antibody Titers and Clinical Outcomes in Patients with Recurrent Miscarriage and Antiphospholipid Antibody Syndrome: A Prospective Study. ( Chi, HB; Liu, P; Qiao, J; Song, Y; Wang, HY, 2017)
" She was started on 100 mg of aspirin, 20 mg of prednisolone and 20 mg of subcutaneous low-molecular-weight heparin daily for her fourth pregnancy."	3.83	Repeated failed non-invasive prenatal testing in a woman with immune thrombocytopenia and antiphospholipid syndrome: lessons learnt. ( Hui, CY; Tan, EL; Tan, LK; Tan, WC, 2016)
"The effect of low-dose aspirin (LDA) on pregnancy outcome in antiphospholipid (aPL)-positive women not fulfilling the criteria for antiphospholipid antibody syndrome (APS) was evaluated retrospectively."	3.79	Treatment of 139 pregnancies in antiphospholipid-positive women not fulfilling criteria for antiphospholipid syndrome: a retrospective study. ( Calligaro, A; Del Ross, T; Favaro, M; Hoxha, A; Punzi, L; Ruffatti, A; Tonello, M; Visentin, MS, 2013)
"Women with persistent aPL on aspirin had pregnancy outcomes that were similar to controls."	3.79	Persistent antiphospholipid antibodies do not contribute to adverse pregnancy outcomes. ( Gray, G; Nelson-Piercy, C; Pasupathy, D; Soh, MC, 2013)
"Primary antithrombotic prevention with aspirin is not indicated in asymptomatic patients with confirmed antiphospholipid (aPL) positivity without systemic autoimmune disorders because: a) the estimated prevalence of thrombosis in unselected cases is about 1% patient-years (range 0-2."	3.78	Primary antithrombotic prevention in carriers of antiphospholipid antibodies without systemic autoimmune disorders. ( Finazzi, G, 2012)
"The objective of this study was to assess pregnancy outcome in women with a history of refractory antiphospholipid antibody-associated pregnancy loss(es) who were treated with early low-dose prednisolone in addition to aspirin and heparin."	3.77	First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss. ( Bramham, K; Hunt, BJ; Khamashta, M; Nelson-Piercy, C; Thomas, M, 2011)
" After delivery, aspirin was prescribed to all patients as primary thrombosis prevention."	3.77	Thrombotic events during long-term follow-up of obstetric antiphospholipid syndrome patients. ( Bacri, JL; Caron, C; Dubucquoi, S; Hachulla, E; Hatron, PY; Houfflin-Debarge, V; Kyndt, X; Lambert, M; Launay, D; Lefèvre, G; Quemeneur, T; Subtil, D, 2011)
"Low molecular weight (LMW) heparin, with or without aspirin (acetylsalicylic acid [ASA]), is used to prevent complications in antiphospholipid syndrome in pregnancy."	3.77	Aspirin and heparin effect on basal and antiphospholipid antibody modulation of trophoblast function. ( Abrahams, VM; Brosens, JJ; Chamley, LW; Han, CS; Lockwood, CJ; Mulla, MJ; Paidas, MJ, 2011)
"9 years) with confirmed diagnoses of cerebral infarction and PAS, treated with anticoagulants (n = 54) or aspirin (n = 38) were retrospectively analyzed."	3.77	[Aspirin versus anticoagulation in young patients with cerebral infarction secondary to primary antiphospholipid syndrome]. ( Arauz, A; Artigas, C; Barinagarrementeria, F; Cantu-Brito, C; Hernandez, B; Marquez, JM; Merlos, M; Perez, A; Roa, LF, 2011)
"The aim of this retrospective, observational study was to determine the impact of low-dose enoxaparin (20 mg) in conjunction with low-dose aspirin on the pregnancy outcome of women with antiphospholipid syndrome and recurrent miscarriage."	3.75	Treatment of recurrent miscarriage and antiphospholipid syndrome with low-dose enoxaparin and aspirin. ( Li, TC; Makris, M; Metwally, M; Mo, D; Saravelos, S, 2009)
"Management recommendations displayed reasonable consistence: (i) for the use of low-dose aspirin and low-molecular weight heparin during pregnancy and during ovarian stimulation for in vitro fertilization; (ii) against oestrogen-containing oral contraceptives; and (iii) for the use of anticoagulants in the post-partum period."	3.74	Management of the controversial aspects of the antiphospholipid syndrome pregnancies: a guide for clinicians and researchers. ( Erkan, D; Gerosa, M; Lockshin, MD; Meroni, PL; Nuzzo, M; Patel, S; Tincani, A, 2008)
" During pregnancy, aspirin prophylaxis was prescribed and followed by steroids after caesarian section."	3.73	[Acute myocardial infarction complicating primary antiphospholipid syndrome after aspirin and steroids withdrawal]. ( Galicier, L; Guillevin, L; Meune, C; Salengro, E; Spaulding, C; Wahbi, K; Weber, S, 2005)
"To elucidate the efficacy of the treatment using a Japanese-modified Chinese herbal medicine, Sairei-to, and low-dose aspirin with or without a corticosteroid hormone for the patients with adverse pregnancy histories positive for anti-phospholipid antibodies."	3.73	Prophylactic therapy for patients with reproductive failure who were positive for anti-phospholipid antibodies. ( Ishii, K; Kikuchi, A; Nonaka, T; Ooki, I; Takakuwa, K; Tamura, M; Tamura, N; Tanaka, K, 2006)
"The authors describe course and outcome of eight patients with ischemic stroke as the first thrombotic manifestation of antiphospholipid syndrome who received low-dose aspirin as prophylactic treatment."	3.72	Low dose aspirin after ischemic stroke associated with antiphospholipid syndrome. ( de Groot, PG; Derksen, RH; Kappelle, LJ, 2003)
" Out of the 9 pregnancies with high dose low-molecular-weight heparin and low dose aspirin thromboprophylaxis throughout pregnancy 8 were successful (88."	3.72	[Successful high-dose low-molecular-weight heparin thromboprophylaxis in pregnant women with antiphospholipid syndrome]. ( Boda, Z; Kerényi, A; Lakos, G; László, P; Pfliegler, G; Pósán, E; Rázsó, K; Schlammadinger, A, 2003)
" Currently, treatment of patients with the antiphospholipid syndrome includes aspirin, particularly for women with recurrent fetal loss."	3.72	Aspirin inhibits endothelial cell activation induced by antiphospholipid antibodies. ( Boehlen, F; de Moerloose, P; Dunoyer-Geindre, S; Kruithof, EK; Reber, G; Satta-Poschung, N, 2004)
"The present report shows that in treated APS pregnancies: i) aspirin treatment started preconceptionally is an independent and significant prognostic factor associated with favorable fetal outcome; and ii) abnormal velocity waveforms in the umbilical artery predict adverse outcome of pregnancy."	3.71	Risk factors associated with fetal losses in treated antiphospholipid syndrome pregnancies: a multivariate analysis. ( Azulay, M; Balasch, J; Carmona, F; Cervera, R; Creus, M; Fábregues, F; Font, J; Puerto, B, 2001)
" A successful pregnancy outcome was achieved by combined therapy with aspirin, low-molecular-weight heparin, prednisone, and enzyme replacement therapy with imiglucerase."	3.71	Successful pregnancy outcome in a patient with Gaucher's disease and antiphospholipid syndrome. ( Dulitzki, M; Langevitz, P; Levy, Y; Livneh, A; Sherer, Y; Shoenfeld, Y, 2002)
"Heparin plus aspirin significantly improves the live birth rate of women with primary antiphospholipid syndrome."	3.70	Bone density changes in pregnant women treated with heparin: a prospective, longitudinal study. ( Backos, M; Doré, C; Murphy, M; Rai, R; Regan, L; Thomas, E, 1999)
" Aspirin, 75 mg daily was given in addition to enoxaparin to women with antiphospholipid syndrome."	3.70	Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. ( Blumenfeld, Z; Brenner, B; Hoffman, R; Weiner, Z; Younis, JS, 2000)
"Our study demonstrates high prevalence of aCL in children who suffer acute cerebral infarction and our results suggest aspirin may be effective therapy to prevent recurrences."	3.69	Cerebral infarction and antiphospholipid syndrome in children. ( Baca, V; Garcia-Ramirez, R; Lavalle, C; Marquez-Enriquez, L; Martinez, I; Ramirez-Lacayo, M, 1996)
"The aim of this study was to determine the neonatal outcome in women with well-characterized antiphospholipid syndrome treated during pregnancy with low-dose aspirin."	3.69	Neonatal outcome in women treated for the antiphospholipid syndrome during pregnancy. ( Balasch, J; Botet, F; Carmona, F; Figueras, J; Montagut, P; Romera, G, 1997)
"Treatment with warfarin was most effective in preventing recurrent arterial and venous thrombosis."	3.69	A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis. ( Harris, EN; Krnic-Barrie, S; Looney, SW; O'Connor, CR; Pierangeli, SS, 1997)
" In 1982, it was suggested for the first time low doses of aspirin and prednisone for treatment of recurrent fetal death associated to this syndrome, heparin therapy was reported in 1984, recommended a doses of 15,000 U/day during first pregnancy trimester and 20,000 U/day posteriorly."	3.69	[Recurrent fetal death and antiphospholipid antibody syndrome. A case report]. ( Bustos López, HH; Hernández Andrade, E; Ramírez Peredo, J; Rojas-Poceros, G, 1997)
"To evaluate the effect of aspirin treatment upon fetal loss in mice with experimental antiphospholipid syndrome (APLS)."	3.68	The effect of aspirin on recurrent fetal loss in experimental antiphospholipid syndrome. ( Blank, M; Gilbrut, B; Krause, I; Shoenfeld, Y, 1993)
"A patient with systemic lupus erythematosus and elevated cardiolipin antibody levels was given low-dose aspirin therapy prior to and throughout her third pregnancy to minimize the risk of miscarriage."	3.68	Anticardiolipin syndrome, aspirin therapy and fetal malformation. ( Chakravarty, K; Merry, P, 1993)
"We reviewed 82 consecutive pregnancies in 54 women with antiphospholipid syndrome who were treated during pregnancy with the following: 1) prednisone and low-dose aspirin; 2) heparin and low-dose aspirin; 3) prednisone, heparin, and low-dose aspirin; or 4) other combinations of these medications or immunoglobulin."	3.68	Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. ( Blackwell, JL; Branch, DW; Reading, JC; Scott, JR; Silver, RM, 1992)
"Treatment with prednisone and aspirin appears to be efficacious, safe, and economic in the prevention of pregnancy loss and fetal growth retardation in patients with aCL."	3.68	Prevention of anticardiolipin antibody-related pregnancy losses with prednisone and aspirin. ( Angel, J; Espinoza, LR; Hubble, CL; Jara, LJ; Martínez-Osuna, P; O'Brien, W; Saway, S; Seleznick, MJ; Silveira, LH, 1992)
" Immunoadsorbent plasmapheresis with a dextran sulphate column was used to remove lupus anticoagulant, anticardiolipin antibodies, and antibodies to DNA during her fourth pregnancy in combination with low doses of aspirin and prednisolone."	3.68	Immunoadsorbent plasmapheresis for a patient with antiphospholipid syndrome during pregnancy. ( Hashimoto, H; Hirose, S; Kobayashi, S; Mokuno, C; Tamura, N; Tsuda, H, 1992)
"Hydroxychloroquine (HCQ) is an immunomodulatory agent that has been shown in laboratory studies to decrease thrombosis risk, support placentation, and minimize the destructive effects of antiphospholipid antibodies."	3.01	Does adding hydroxychloroquine to empiric treatment improve the live birth rate in refractory obstetrical antiphospholipid syndrome? A systematic review. ( Bacal, V; Bedaiwy, MA; Hooper, A, 2023)
" Six hundred eighty-seven APA+ women, who were younger than 40 years and who each, completed up to three consecutive IVF/embryo transfer cycles within a 12-month period, were given either H/A alone or H/A in combination with IVIg."	2.69	The selective use of heparin/aspirin therapy, alone or in combination with intravenous immunoglobulin G, in the management of antiphospholipid antibody-positive women undergoing in vitro fertilization. ( Ching, W; Chong, P; Feinman, M; Maassarani, G; Matzner, W; Sher, G; Zouves, C, 1998)
"Treatment with aspirin and heparin leads to a significantly higher rate of live births in women with a history of recurrent miscarriage associated with phospholipid antibodies than that achieved with aspirin alone."	2.68	Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies) ( Cohen, H; Dave, M; Rai, R; Regan, L, 1997)
"Placenta-mediated pregnancy complications are clinically important conditions and include preeclampsia, placental abruption, intrauterine growth restriction, and late fetal loss."	2.66	Understanding and Preventing Placenta-Mediated Pregnancy Complications. ( Blondon, M; Ní Áinle, F; Skeith, L, 2020)
"Today, pregnancy is no longer considered impossible in women with lupus."	2.53	Pregnancy in women with systemic lupus erythematosus (SLE). ( Moroni, G; Ponticelli, C, 2016)
" Careful attention must be paid to the dosing and potential teratogenicity of medications."	2.52	Pregnancy and Lupus Nephritis. ( Garovic, VD; Kattah, AG, 2015)
"Obstetric antiphospholipid antibody syndrome (APS) is diagnosed in the presence of certain clinical features in conjunction with positive laboratory findings."	2.50	Antiphospholipid antibody syndrome. ( Hinote, CD; Kutteh, WH, 2014)
"The optimum treatment for patients with recurrent miscarriage and a confirmed thrombophilia remains a contentious issue."	2.48	Recurrent miscarriage and thrombophilia: an update. ( Dawood, F; Farquharson, R; McNamee, K, 2012)
"Antiphospholipid syndrome is a rare cause of ocular vaso-occlusive disease, but is associated with significant systemic morbidity and mortality."	2.48	Antiphospholipid antibody syndrome. ( Foster, CS; Kruh, JN; Yang, P, 2012)
"Treatment with aspirin and heparin decreases the risk of miscarriages in APS."	2.47	Heparin or aspirin or both in the treatment of recurrent abortions in women with antiphospholipid antibody (syndrome). ( Burmester, GR; Dörner, T; Hoppe, B, 2011)
"Obstetric antiphospholipid antibody syndrome (APS) is diagnosed in the presence of certain clinical features in conjunction with positive laboratory findings."	2.47	Obstetric antiphospholipid syndrome: an update on pathophysiology and management. ( Ernest, JM; Kutteh, WH; Marshburn, PB, 2011)
"Antiphospholipid syndrome is one of the few treatable causes of pregnancy loss, and successful pregnancy rates of 70% or more can be achieved with appropriate treatment."	2.44	[Pregnancy and antiphospholipid antibodies]. ( Goffinet, F; Le Guern, V, 2008)
"Antiphospholipid syndrome is considered to be associated with a hypercoagulable state that leads to stroke and other ischemic events, and is currently diagnosed based on the modified Sapporo criteria that was proposed in 2006."	2.44	[Ischemic stroke with antiphospholipid antibody]. ( Kitagawa, Y; Ohkuma, H; Tokuoka, K, 2008)
"The antiphospholipid syndrome is an antibody mediated hypercoagulable state characterized by recurrent venous and arterial thromboembolic events."	2.44	[The antiphospholipid syndrome, an update]. ( Alonso Santor, JE; Inglada Galiana, L; Pérez Paredes, G, 2007)
"The antiphospholipid syndrome is currently best treated with anticoagulation."	2.43	Anticoagulation therapy in the antiphospholipid syndrome: recent advances. ( Crowther, MA; Ng, HJ, 2005)
"Women with systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) are subject to several complications during pregnancy, including reactivation of SLE, thrombosis, miscarriage, neonatal lupus, pregnancy-induced hypertension, pulmonary hypertension and drug toxicity."	2.43	[Systematic lupus erythematosus and antiphospholipid syndrome during pregnancy]. ( Khamashta, MA; Ruiz-Irastorza, G, 2006)
"The 'antiphospholipid antibody syndrome' has been described in women with a history of recurrent pregnancy loss or thrombosis with positive APA or lupus anticoagulant on two occasions."	2.42	Low molecular weight heparin in immunological recurrent abortion--the incredible cure. ( Allahbadia, GN; Allahbadia, SG, 2003)
"The risk of preeclampsia and placental insufficiency was substantial and occurred in 50% of patients."	2.42	Antiphospholipid syndrome in obstetrics. ( Heilmann, L; Pollow, K; von Tempelhoff, GF, 2003)
"Since 1987 the antiphospholipid syndrome has been recognized as a major cause of acquired thrombophilia, whether it is associated with systemic lupus erythematosus or occurs as a free-standing syndrome (primary form)."	2.41	[Antiphospholipid syndrome]. ( Arvieux, J; Hachulla, E, 2002)
"Antiphospholipid syndrome is a multisystem disease with the predominant features of venous and arterial thrombosis, recurrent pregnancy loss, foetal death and the presence of antiphospholipid antibodies."	2.41	Antiphospholipid syndrome and recurrent miscarriages. ( Cosson, M; Dufour, P; Houpeau, JL; Vinatier, D, 2001)
"If diagnosed and treated early in pregnancy with low-dose aspirin and subcutaneous heparin the outlook for a successful pregnancy is much improved."	2.41	A literature review on the antiphospholipid syndrome and the effect on childbearing. ( Vials, JM, 2001)
"Arterial and venous thrombosis are the most common and clinically relevant events of the so-called antiphospholipid syndrome; they are reported in approximately one third of patients with the antiphospholipid (aPL) antibodies."	2.41	The epidemiology of the antiphospholipid syndrome: who is at risk? ( Finazzi, G, 2001)
"Under corticosteroid treatment, chorea disappeared and cardiac involvement stabilised."	2.40	Chorea as the presenting clinical feature of primary antiphospholipid syndrome in childhood. ( Ellemunter, H; Kiechl, S; Kiechl-Kohlendorfer, U, 1999)
"Common complications of systemic lupus erythematosus include nephritis, hematologic complications such as thrombocytopenia, and a variety of neurologic abnormalities."	1.91	Society for Maternal-Fetal Medicine Consult Series #64: Systemic lupus erythematosus in pregnancy. ( Craigo, S; Kuller, JA; Norton, ME; Osmundson, SS; Porter, F; Silver, R, 2023)
" In age-adjusted analyses, aspirin plus LMWH regardless of dosage was associated with significantly higher odds of live birth compared with no antithrombotic use (OR = 7."	1.91	Management and outcomes of women with antiphospholipid syndrome during pregnancy. ( Adurty, S; D'Angelo, D; DeSancho, MT; Tao, JJ, 2023)
"Antiphospholipid syndrome is associated with recurrent pregnancy loss."	1.62	"Part of the Ritual": Exploring Patient and Physician Decision Making Regarding Anticoagulation Use in Obstetric Antiphospholipid Syndrome. ( Bates, SM; Gonsalves, C; Karovitch, A; Rodger, MA; Skeith, L; Taylor, TS, 2021)
"A 50-year-old woman with a history of Crohn's disease treated with adalimumab presented with left hand pain and duskiness."	1.56	Digital ischaemia secondary to adalimumab-induced antiphospholipid syndrome. ( Cheemalavagu, S; Knight, JS; McCoy, SS, 2020)
"In this series, recurrent miscarriage is the most frequent poor outcome."	1.51	The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases. ( Alijotas-Reig, J; Arnau, A; Belizna, C; Canti, V; Cervera, R; Chighizola, CB; De Carolis, S; Espinosa, G; Esteve-Valverde, E; Farran-Codina, I; Ferrer-Oliveras, R; Gerosa, M; Gogou, V; Hoxha, A; Latino, O; Lefkou, E; LLurba, E; Lundelin, K; Marozio, L; Martí-Cañamares, A; Mayer-Pickel, K; Mekinian, A; Pengo, V; Reshetnyak, T; Ríos-Garcés, R; Rovere-Querini, P; Ruffatti, A; Ruiz-Hidalgo, D; Sáez-Comet, L; Sos, L; Stojanovich, L; Stoppani, C; Tabacco, S; Tincani, A; Trapé, J; Varoudis, A, 2019)
"Recurrent spontaneous abortion is one of the common complications in women of childbearing age during pregnancy."	1.48	[Diagnosis and treatment of antiphospholipid antibody-related recurrent spontaneous abortion and analysis of therapeutic drugs and pregnancy outcome in 75 patients with antiphospholipid syndrome]. ( Li, XY; Liu, XY; Zhao, JX, 2018)
"Antiphospholipid syndrome is an autoimmune, hypercoagulable state that is caused by antiphospholipid antibodies."	1.46	Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: the PREGNANTS study. ( Berghella, V; Bernabini, D; Dall'Asta, A; Eke, AC; Facchinetti, F; Ghi, T; Hoxha, A; Martinelli, P; Maruotti, GM; Monari, F; Rizzo, G; Rizzo, N; Roman, A; Ruffatti, A; Saccone, G; Sarno, L; Schuit, E; Simonazzi, G; Visentin, S; Xodo, S, 2017)
"Obstetrical APS with isolated recurrent miscarriages is mostly associated with isolated anticardiolipids antibodies and have better obstetrical outcome."	1.46	[Obstetrical APS: Is there a place for additional treatment to aspirin-heparin combination?] ( Abisror, N; Bornes, M; Carbillon, L; Cohen, J; Fain, O; Josselin-Mahr, L; Kayem, G; Mekinian, A, 2017)
"In univariate analyses, treatment effect on pregnancy losses was similar in patients with APS and non-conventional APS, with odds ratio at 3."	1.43	Non-conventional antiphospholipid antibodies in patients with clinical obstetrical APS: Prevalence and treatment efficacy in pregnancies. ( Benbara, A; Bourrienne, MC; Carbillon, L; Chollet-Martin, S; Fain, O; Mekinian, A; Montestruc, F; Nicaise-Roland, P; Noémie, A; Tigaizin, A, 2016)
"Antiphospholipid syndrome is an autoimmune disorder characterized by the occurrence of venous and arterial thrombosis, as well as morbidity in pregnancy, in the presence of anti-phospholipid antibodies."	1.42	Elevated levels of antibodies against phosphatidylserine/prothrombin complex and/or cardiolipin associated with infection and recurrent purpura in a child: a forme fruste of antiphospholipid syndrome? ( Igarashi, T; Inaba, M; Katagiri, I; Kawana, S; Kinoshita, Y; Mayumi, N, 2015)
"The number of cases of aPL-related pregnancy complications that physicians have intervened was relatively small."	1.42	The participations of the physicians on the diagnosis and treatments of antiphospholipid related pregnancy morbidities in Japan: from the result of nationwide survey. ( Amengual, O; Atsumi, T; Bohgaki, T; Horita, T; Kaneko, K; Murashima, A; Nakanishi, I; Nozawa, K; Oku, K; Oomura, K; Sugiura-Ogasawara, M; Yasuda, S, 2015)
"(2) Influence of treatment on the pregnancy outcomes and complications: 24 APS patients were given the treatment of aspirin or aspirin combined with low molecular weight heparin, and 30 patients received no treatment."	1.40	[Pregnancy outcome in 54 patients with antiphospholipid syndrome: a retrospective clinical study]. ( Deng, XL; Liu, XY; Zheng, XJ, 2014)
"Previous thrombosis, diagnosis of systemic lupus erythematosus (SLE) and triple antiphospholipid (aPL) antibody positivity have recently been found to be independent factors associated to pregnancy failure during conventional therapy in women with antiphospholipid syndrome (APS)."	1.40	Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. A European multicentre retrospective study. ( Alijotas-Reig, J; Andreoli, L; Bertero, MT; Bremme, K; Brucato, A; Canti, V; Caramaschi, P; De Carolis, S; Del Ross, T; Di Poi, E; Galeazzi, M; Gerosa, M; Maina, A; Mekinian, A; Meroni, PL; Mosca, M; Ramoni, V; Ruffatti, A; Salvan, E; Tincani, A; Trespidi, L, 2014)
"The risk for preeclampsia increased in patients who were positive for multiple antiphospholipid antibodies (aPL) (odds ratio (OR) 3."	1.38	Pregnancy outcome in patients with antiphospholipid syndrome after cerebral ischaemic events: an observational study. ( Brinks, R; Fischer-Betz, R; Schneider, M; Specker, C, 2012)
"Shrinking lung syndrome is characterized by pulmonary compromise secondary to unilateral or bilateral paralysis of the diaphragm."	1.37	Shrinking lung syndrome in pregnancy complicated by antiphospholipid antibody syndrome. ( Brost, BC; DeStephano, CC; Meena, M; Watson, WJ, 2011)
"To describe the diagnosis and treatment of antiphospholipid syndrome as it relates to spontaneous abortion."	1.37	A practical approach to the prevention of miscarriage: part 5--antiphospholipid syndrome as a cause of spontaneous abortion. ( Check, JH, 2011)
"Treatment with aspirin and LMWH is associated with improved outcomes for women with previous late fetal loss or early delivery due to placental dysfunction (Group 2)."	1.36	Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome. ( Bewley, S; Bramham, K; Calatayud, I; Germain, S; Hunt, BJ; Khamashta, M; Nelson-Piercy, C, 2010)
"Thus, in order to diagnose and treat pregnancy-triggered APS in patients with unexplained recurrent miscarriage, screening for APL should also be performed at several time points after conception."	1.36	Pregnancy-triggered antiphospholipid syndrome in a patient with multiple late miscarriages. ( Engel, JB; Häusler, S; Honig, A; Kranke, P; Segerer, SE; Würfel, W, 2010)
"Thrombosis is the most frequent clinical manifestation of APS."	1.35	[Antiphospholipid antibody syndrome]. ( Chakoutio, V; Ries, F, 2009)
"Between 20% and 40% of patients with systemic lupus erythematosus (SLE) have positive blood tests for antiphospholipid antibodies (aPLs)."	1.35	How to manage patients with systemic lupus erythematosus who are also antiphospholipid antibody positive. ( Giles, I; Rahman, A, 2009)
"The classical clinical picture of antiphospholipid antibody syndrome (APS) is characterized by venous and arterial thrombosis, fetal losses and thrombocytopenia in the presence of anticardiolipin antibodies and/or lupus anticoagulant."	1.35	Paediatric case report: primary antiphospholipid syndrome presented with non-thrombotic neurological picture psychosis; treat by antidepressants alone? ( Alhumayed, S; Alshehri, A; Shabana, M; Shalaby, M, 2009)
"Antiphospholipid syndrome is a recognized disorder of pregnancy."	1.33	Maternal and fetal complications of antiphospholipid syndrome: a case report with long-term follow-up. ( Khurshid, M; Naru, T; Nazir, Z, 2006)
"Aspirin was recommended to reduce the risk of future thromboses."	1.32	Antiphospholipid antibody syndrome in a six-year-old female patient. ( Hartnett, ME; Laposata, M; Van Cott, E, 2003)
"On administration of low-molecular heparin, its dosage weight-adjusted, and 100 mg aspirin daily the discoloration of the finger quickly disappeared, but Raynaud's syndrome remained unchanged until she had stopped breast feeding (left breast only) after 8 months."	1.32	[Repeated attacks of pain in the nipple of a pregnant woman. Unusual manifestation of Raynaud's phenomenon]. ( Diehm, C; Lawall, H; Stammler, F, 2003)
"Her blood test indicated existence of antiphospholipid antibody syndrome (APS) complicated with mixed connective tissue disease as an etiology of this uncommon carotid thrombus."	1.32	[Embolic stroke with mobile thrombus in carotid artery induced by antiphospholipid antibody syndrome]. ( Fujimoto, S; Hagiwara, N; Nishimura, Y; Okada, Y; Toyoda, K, 2003)
"Autoimmune diseases are a group of illnesses in which autoantibodies are produced against various organs, presenting with a variety of clinical symptoms."	1.32	Maternal autoimmune diseases and immunologically induced embryonic and fetoplacental damage. ( Chen, L; Miller, RK; Ornoy, A; Silver, RM, 2004)
"Severe bleeding was defined by the need for admission to hospital."	1.31	Characteristics of patients with antiphospholipid syndrome with major bleeding after oral anticoagulant treatment. ( Castellino, G; Cuadrado, MJ; Godfrey, T; Hughes, GR; Khamashta, MA, 2001)
"We present a case of antiphospholipid antibody syndrome (APS) with repeated transient ischemic attacks (TIAs)."	1.31	Technetium-99m-ECD SPECT in antiphospholipid antibody syndrome: a drastic improvement in brain perfusion by antiplatelet therapy. ( Kudo, S; Kuroda, Y; Matsui, M; Tokumaru, S; Uchino, A; Yoshikai, T, 2001)
"Patients with antiphospholipid antibody syndrome (APS) have a high risk for rethrombosis."	1.31	Longterm anticoagulation is preferable for patients with antiphospholipid antibody syndrome. result of a decision analysis. ( Brunner, HI; Chan, WS; Feldman, BM; Ginsberg, JS, 2002)
"Treatment with prednisolone (7."	1.30	[A case of antiphospholipid antibody syndrome successfully treated with prednisolone and low-dose aspirin, with subsequent normal pregnancy]. ( Maeda, T; Maesima, E; Yamada, Y; Yamamoto, M; Yukawa, S, 1997)
"Patients with antiphospholipid syndrome are at high risk of pregnancy loss as well as maternal morbidity, especially thrombo-embolic disease."	1.30	Obstetric outcome in antiphospholipid syndrome. ( Farquharson, RG; Granger, KA, 1997)
"The mesenteric infarction is a rare but life threatening cause of acute abdomen."	1.30	[Mesenteric infarct in primary antiphospholipid antibody syndrome]. ( Buck, J; Eder, A; Heinkelein, J; Kurz, R, 1997)
"A diagnosis of mixed connective tissue disease (Sharp-syndrome) was established."	1.30	[A patient with mixed collagen disease, antiphospholipid syndrome and Sjögren syndrome]. ( Hartmann, F; Kranzhöfer, N; Lindemuth, R; Zuber, M, 1998)
"Thromboembolism is a common occurrence in patients with the antiphospholipid syndrome (APS)."	1.30	Platelet activation and turnover in the primary antiphospholipid syndrome. ( Donohoe, S; Harrison, P; Joseph, JE; Machin, SJ; Mackie, IJ, 1998)
"Aspirin acts as a potent stimulator of IL-3 through its ability to raise leukotriene production, which induces production of IL-3 both in vitro and in vivo."	1.29	Aspirin modulates interleukin-3 production: additional explanation for the preventive effects of aspirin in antiphospholipid antibody syndrome. ( Falach-Vaknin, E; Fishman, P; Meroni, PL; Rudniki, C; Shoenfeld, Y; Sredni, B, 1995)
"The rate of recurrence of thrombosis was highest (1."	1.29	The management of thrombosis in the antiphospholipid-antibody syndrome. ( Cuadrado, MJ; Hughes, GR; Hunt, BJ; Khamashta, MA; Mujic, F; Taub, NA, 1995)
"The patient had experienced hepatic infarction during her first pregnancy and had repeated hepatic infarction during her third pregnancy."	1.29	Hepatic infarction during pregnancy complicated by antiphospholipid syndrome. ( Kinoshita, K, 1993)
"Five warfarin-treated patients had five significant bleeding events (0."	1.28	Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. ( Brewer, PM; Rosove, MH, 1992)
"Eight patients, 3 with systemic lupus erythematosus (SLE) or "SLE-like" disease, 1 with sarcoidosis, and 4 with no connective tissue disease had transient ischemic attacks (TIA) or cerebral infarctions associated with high levels of anticardiolipin antibodies (ACA)."	1.28	Cerebral ischemia associated with anticardiolipin antibodies. ( Ernerudh, J; Lindström, F; Olsson, JE; Vrethem, M, 1992)
" While steroid dosage was gradually decreased, administration of acetylsalicylic acid (for three months 100 mg daily, then three times daily 100 mg) brought about complete disappearance of the visual signs."	1.28	[The antiphospholipid syndrome. The neurological complications and the therapeutic possibilities]. ( Berg, PA; Leo-Kottler, B; Weller, M; Wiethölter, H, 1991)

Research

Studies (406)

Authors

Clinical Trials (11)

Trial Overview

Trial Outcomes

Live Birth Rate = (Number of Live Births / Total Number of Pregnancies)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	103 (25.37)	18.2507
2000's	160 (39.41)	29.6817
2010's	110 (27.09)	24.3611
2020's	33 (8.13)	2.80

Authors	Studies
Hussain, H	1
Tarantino, MD	1
Chaturvedi, S	1
McCrae, KR	1
Roberts, JC	1
Udry, S	4
Peréz, SM	1
Belizna, C	5
Aranda, F	2
Esteve-Valverde, E	3
Wingeyer, SP	2
Fernández-Romero, DS	1
Latino, JO	3
de Larrañaga, G	1
Alijotas-Reig, J	9
Pires da Rosa, G	1
Ferreira, E	1
Sousa-Pinto, B	1
Rodríguez-Pintó, I	2
Brito, I	1
Mota, A	1
Cervera, R	12
Espinosa, G	6
Silver, R	1
Craigo, S	1
Porter, F	1
Osmundson, SS	1
Kuller, JA	1
Norton, ME	1
Gris, JC	3
Bourguignon, C	1
Bouvier, S	2
Nouvellon, É	1
Laurent, J	1
Perez-Martin, A	2
Mousty, È	2
Nikolaeva, MG	1
Khizroeva, J	2
Bitsadze, V	2
Makatsariya, A	2
Ambati, A	1
Knight, JS	3
Zuo, Y	2
Tao, JJ	1
Adurty, S	1
D'Angelo, D	1
DeSancho, MT	1
Regan, L	7
Rai, R	7
Saravelos, S	2
Li, TC	3
Porta, SV	1
de Andrade, DCO	1
Erkan, D	6
Gómez-Puerta, JA	1
Jara, LJ	2
Alba Moreyra, P	1
Pons-Estel, GJ	1
Granada-Gómez, M	1
Velásquez-Berrío, M	1
Molina, CR	1
Martín, SS	1
Escudero, C	1
Alvarez, AM	2
Cadavid, AP	2
Hooper, A	1
Bacal, V	1
Bedaiwy, MA	1
Lazzaroni, MG	3
Fredi, M	2
Andreoli, L	7
Chighizola, CB	4
Del Ross, T	6
Gerosa, M	6
Kuzenko, A	1
Raimondo, MG	1
Lojacono, A	2
Ramazzotto, F	1
Zatti, S	2
Trespidi, L	3
Meroni, PL	7
Pengo, V	5
Ruffatti, A	12
Tincani, A	13
Wang, M	2
Zhang, P	1
Yu, S	1
Zhou, G	1
Lv, J	1
Nallapothula, D	1
Guo, C	1
Wang, Q	1
Singh, RR	1
Ferrer-Oliveras, R	4
Sáez-Comet, L	2
Lefkou, E	3
Mekinian, A	9
Hoxha, A	7
Nalli, C	1
Marozio, L	2
Maina, A	3
Ríos-Garcés, R	2
Carolis, S	1
Monteleone, G	1
Latino, O	2
LLurba, E	2
Garrido-Gimenez, C	1
Rovere-Querini, P	3
Canti, V	4
Mayer-Pickel, K	2
Tabacco, S	3
Arnau, A	2
Trapé, J	2
Ruiz-Hidalgo, D	2
Sos, L	2
Farran-Codina, I	2
Favaro, M	4
Calligaro, A	4
Ruffatti, AT	2
Infantolino, C	1
Tonello, M	4
Mattia, E	1
Arslan, E	1
Branch, DW	6
Liu, X	1
Qiu, Y	1
Yu, ED	1
Xiang, S	1
Meng, R	1
Niu, KF	1
Zhu, H	1
Cheemalavagu, S	1
McCoy, SS	1
Radin, M	2
Cecchi, I	1
Schreiber, K	5
Rubini, E	1
Roccatello, D	2
Cuadrado, MJ	5
Sciascia, S	5
Bao, SH	2
Frempong, ST	2
Ruan, JL	1
Madison, JA	1
Duarte-García, A	1
Skeith, L	2
Blondon, M	1
Ní Áinle, F	1
Romero, DSF	1
Larrañaga, G	1
Varoudi, K	1
Pombo, J	1
Jurisic, A	1
Jurisic, Z	1
Contento, G	1
Girardi, G	1
Yang, Z	1
Shen, X	1
Zhou, C	1
Liu, Y	2
Zhou, L	1
Gervasi, MT	1
Schofield, JR	1
Hughes, HN	1
Birlea, M	1
Hassell, KL	1
Rodger, MA	1
Bates, SM	1
Gonsalves, C	1
Karovitch, A	1
Taylor, TS	1
Lee, EE	1
Jun, JK	1
Lee, EB	1
Benito-Garcia, F	1
Pires, I	1
Lima, J	1
Arslanbekova, M	1
Babaeva, N	1
Tsibizova, V	1
Shkoda, A	1
Makatsariya, N	1
Tretyakova, M	1
Solopova, A	1
Gadaeva, Z	1
Vorobev, A	1
Khamani, I	1
Aslanova, Z	1
Nakaidze, I	1
Mischenko, A	1
Grigoreva, K	1
Kunesko, N	1
Egorova, E	1
Mashkova, T	1
Shi, T	1
Gu, ZD	1
Diao, QZ	1
Li, X	1
Shopit, A	1
Wang, J	1
Madar, H	1
Brun, S	1
Coatleven, F	1
Nithart, A	1
Lecoq, C	1
Gleyze, M	1
Merlot, B	1
Sentilhes, L	1
Comarmond, C	1
Jego, P	2
Veyssier-Belot, C	1
Marie, I	1
Elmaleh-Sachs, A	1
Leroux, G	1
Saadoun, D	2
Oziol, E	1
Fraisse, T	1
Hyvernat, H	1
Thiercein-Legrand, MF	1
Sarrot-Reynauld, F	1
Ferreira-Maldent, N	1
de Menthon, M	1
Goujard, C	1
Khau, D	1
Nguen, Y	1
Monnier, S	1
Michon, A	1
Castel, B	1
Decaux, O	1
Piette, JC	6
Cacoub, P	1
Carrat, F	2
Costedoat-Chalumeau, N	4
Masseau, A	1
Morel, N	3
Esteve-Valverde, EE	1
De Carolis, S	6
Josselin-Mahr, L	2
Abisror, N	2
Nicaise-Roland, P	3
Fain, O	5
Riancho-Zarrabeitia, L	1
Daroca, G	1
Muñoz, P	1
López-Hoyos, M	1
Haya, A	1
Martínez-Taboada, VM	1
Yelnik, CM	3
Urbanski, G	2
Drumez, E	3
Caron, C	4
Maillard, H	2
Morell-Dubois, S	3
Dubucquoi, S	4
Launay, D	5
Hachulla, E	7
Hatron, PY	7
Duhamel, A	2
Lambert, M	6
Mahajan, K	1
Negi, P	1
Merwaha, R	1
Sharma, M	1
Deguchi, M	1
Yamada, H	1
Sugiura-Ogasawara, M	2
Morikawa, M	1
Fujita, D	1
Miki, A	1
Makino, S	1
Murashima, A	3
Arnaud, L	2
Conti, F	1
Massaro, L	1
Denas, G	1
Chasset, F	1
Sheng, SL	1
Liao, H	1
Zhou, Q	1
Tu, WY	1
Quao, ZC	1
Tong, M	1
Bryce, E	1
Guller, S	1
Chamley, LW	3
Abrahams, VM	2
Lu, C	1
Jiang, HL	1
de Groot, PG	3
Devreese, K	1
Jacobsen, S	2
Ruiz-Irastorza, G	9
Salmon, JE	4
Shoenfeld, Y	16
Shovman, O	1
Hunt, BJ	10
Aggogeri, E	1
Bettiga, E	1
Le Guern, V	3
DeFilippis, EM	1
Tsao, AL	1
Loscalzo, J	1
Bacri, JL	2
Guerra, MM	2
Laskin, CA	4
Sammaritano, LR	3
Guettrot-Imbert, G	1
Gerardi, MC	1
Fernandes, MA	1
Kemp, M	1
Thomas, W	1
Placais, L	1
Carbillon, L	4
Nicaise Roland, P	1
Benbara, A	2
Cacciatore, C	1
Li, XY	1
Zhao, JX	1
Liu, XY	2
Zambon, A	1
Lundelin, K	1
Reshetnyak, T	1
Stojanovich, L	1
Gogou, V	1
Varoudis, A	1
Stoppani, C	1
Martí-Cañamares, A	1
Visentin, MS	2
Punzi, L	1
Kwak-Kim, J	1
Agcaoili, MS	1
Aleta, L	1
Liao, A	1
Ota, K	1
Dambaeva, S	1
Beaman, K	1
Kim, JW	1
Gilman-Sachs, A	1
Bloor, M	1
Paech, M	1
Soh, MC	1
Pasupathy, D	1
Gray, G	1
Nelson-Piercy, C	5
Bertolaccini, ML	1
Seed, PT	3
Tektonidou, MG	2
Aguirre, A	1
Mico, L	1
Gordon, C	1
Egurbide, MV	2
Gil, A	1
Houssiau, F	1
Rahman, A	2
Martin, H	1
McHugh, N	1
Galindo, M	1
Akil, M	1
Amigo, MC	1
Murru, V	1
Khamashta, MA	16
Mathian, A	1
Tektonidou, M	1
Forastiero, R	1
Martinez-Zamora, MA	1
Balasch, J	7
Zuily, S	1
Wahl, D	3
Amoura, Z	1
de Jesús, GR	1
Rodrigues, G	1
de Jesús, NR	2
Levy, RA	4
Yasuda, S	2
Kutteh, WH	6
Hinote, CD	1
Zheng, XJ	1
Deng, XL	1
de Jong, PG	1
Kaandorp, S	2
Di Nisio, M	2
Goddijn, M	2
Middeldorp, S	3
Salvan, E	1
Bertero, MT	2
Brucato, A	1
Bremme, K	1
Ramoni, V	1
Mosca, M	2
Di Poi, E	1
Caramaschi, P	1
Galeazzi, M	1
Signorelli, F	1
Arachchillage, DR	1
Machin, SJ	3
Mackie, IJ	3
Cohen, H	4
Ramcharan, K	1
Abdool, K	1
Persad, N	1
Dyaanand, H	1
Schmoeller, DG	1
da Silva, BM	1
Staub, HL	1
Dimitrova, V	1
Dimitrov, R	1
Savov, A	1
Pavord, S	1
Khamashta, M	6
Vergallo, R	1
Aguirre, AD	1
Abtahian, F	1
Minami, Y	1
Soeda, T	1
Chatzizisis, YS	1
Croce, K	1
Jang, IK	1
Kim, MY	1
Buyon, JP	2
Rana, S	1
Zhang, D	1
Petri, M	5
Lockshin, MD	5
Porter, TF	1
Merrill, JT	3
Stephenson, MD	3
Gao, Q	1
Karumanchi, SA	1
Kinoshita, Y	1
Mayumi, N	1
Inaba, M	1
Igarashi, T	1
Katagiri, I	1
Kawana, S	1
Kattah, AG	1
Garovic, VD	1
van Hoorn, ME	1
Hague, WM	1
van Pampus, MG	1
Bezemer, D	1
de Vries, JI	2
Ismail, AM	1
Hamed, AH	1
Saso, S	1
Abu-Elhasan, AM	1
Abu-Elghar, MM	1
Abdelmeged, AN	1
Lykke, JA	1
Langhoff-Roos, J	1
Nielsen, HS	1
Oku, K	1
Oomura, K	1
Amengual, O	1
Bohgaki, T	1
Horita, T	1
Kaneko, K	1
Nakanishi, I	1
Nozawa, K	1
Atsumi, T	2
Moroni, G	1
Ponticelli, C	1
Bourrienne, MC	1
Noémie, A	1
Chollet-Martin, S	2
Tigaizin, A	1
Montestruc, F	1
Sobanski, V	1
Lanteri, A	1
Costantine, MM	1
Abheiden, CN	1
Blomjous, BS	1
Kroese, SJ	1
Bultink, IE	1
Fritsch-Stork, RD	1
Lely, AT	1
de Boer, MA	1
Herrera, CA	1
Heuser, CC	1
Lim, W	2
Hui, CY	1
Tan, WC	1
Tan, EL	1
Tan, LK	1
Cochery-Nouvellon, É	1
Mercier, É	1
Balducchi, JP	2
Quéré, I	2
Letouzey, V	1
Balcázar, N	1
San Martín, S	1
Markert, UR	1
Song, Y	1
Wang, HY	1
Qiao, J	1
Liu, P	1
Chi, HB	1
Saccone, G	1
Berghella, V	1
Maruotti, GM	1
Ghi, T	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)[NCT00198068]		700 participants (Anticipated)	Observational	2003-09-30	Recruiting
Hydroxychloroquine in Unexplained Recurrent Pregnancy Loss ,Double Blinded Randomized Controlled Trial .[NCT05237843]	Phase 1	70 participants (Anticipated)	Interventional	2022-03-01	Not yet recruiting
A Multicenter, Double-blind, Randomized and Parallel Controlled Study of Hydroxychloroquine Sulfate in the Treatment of Recurrent Miscarriage With Antiphospholipid Syndrome[NCT04624269]	Phase 4	384 participants (Anticipated)	Interventional	2020-12-01	Not yet recruiting
A Randomized Clinical Trial of Using Preconceptional Enoxaparin AND Low Dose Aspirin 81mg in Patient With Antiphospholipid Syndrome(APS)[NCT01661439]		316 participants (Anticipated)	Observational	2012-03-31	Recruiting
Low-molecular-weight Heparin Versus Unfractionated Heparin in Pregnant Women With History of Recurrent Abortion Secondary to Antiphospholipid Syndrome. A Randomized Controlled Trial[NCT01051778]	Phase 2	60 participants (Actual)	Interventional	2006-06-30	Completed
Association Between Preeclampsia, Antiphospholipid Syndrome and Postpartum Pulmonary Artery Pressure, Systemic Arterial Pressure and Cardiovascular Function.[NCT05679206]		900 participants (Anticipated)	Observational	2022-12-20	Recruiting
Evaluation of the Benefit of Adjuvant Treatment With Hydroxychloroquine to the Usual Medical Management for Obtaining an Uncomplicated Term Pregnancy in Primary Obstetric Antiphospholipid Syndrome[NCT04275778]	Phase 2	110 participants (Anticipated)	Interventional	2021-07-09	Recruiting
Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin as Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE (APS-STROKE)[NCT05995600]	Phase 4	400 participants (Anticipated)	Interventional	2023-12-31	Not yet recruiting
Apixaban for the Secondary Prevention of Thromboembolism: a Prospective Randomized Outcome Pilot Study Among Patients With the AntiphosPholipid Syndrome[NCT02295475]	Phase 4	48 participants (Actual)	Interventional	2014-12-10	Completed
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)[NCT02409680]		11,976 participants (Actual)	Interventional	2016-03-23	Completed
Low Dose Prednisone Therapy in Women With Recurrent Pregnancy Loss[NCT04558268]	Phase 2/Phase 3	242 participants (Anticipated)	Interventional	2020-12-31	Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Live birth occurs when a fetus (> 24 weeks ) , exits the maternal body and subsequently shows signs of life, such as voluntary movement, heartbeat, or pulsation of the umbilical cord. (NCT01051778)
Timeframe: pregnancy > 24weeks gestation

Fetal Outcome 1 - Incidence of Early Preterm Delivery (<34 Weeks)

Fetal Outcome 2 - Incidence of Actual Birth Weight <2500g

Fetal Outcome 3 - Incidence of Actual Birth Weight <1500g

Fetal Outcome 4 - Incidence of Fetal Loss

Fetal Outcome 5 - Incidence of Spontaneous Abortion

Fetal Outcome 6 - Incidence of All Stillbirth

Fetal Outcome 7 - Incidence of Medical Termination of Pregnancy

Intervention	Percentage of pregnancies (Number)
Enoxaparin 40 mg /Day Plus Low Dose Aspirin	24
Heparin Calcium 5,000 U Twice Daily Plus Low Dose Aspirin	20

Intervention	Participants (Count of Participants)
Intervention Arm	189
Placebo Arm	230

Intervention	Participants (Count of Participants)
Intervention Arm	1078
Placebo Arm	1153

Intervention	Participants (Count of Participants)
Intervention Arm	78
Placebo Arm	101

Intervention	Participants (Count of Participants)
Intervention Arm	303
Placebo Arm	353

Intervention	Participants (Count of Participants)
Intervention Arm	134
Placebo Arm	152

Intervention	Participants (Count of Participants)
Intervention Arm	141
Placebo Arm	166

- Incidence of Medical Termination of Pregnancy (NCT02409680)
Timeframe: At delivery

Incidence of Hypertensive Disorders of Pregnancy

Intervention	Participants (Count of Participants)
Intervention Arm	42
Placebo Arm	30

- Hypertensive disorders of pregnancy is defined by the characterization of evidence of a hypertensive disorder, including either preeclampsia or eclampsia occurring during the pregnancy. (NCT02409680)
Timeframe: Evidence of hypertensive disorder during the pregnancy (prior to delivery/birth)

Incidence of Perinatal Mortality

Intervention	Participants (Count of Participants)
Intervention Arm	352
Placebo Arm	325

- Incidence of Perinatal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

Incidence of Preterm Birth

Intervention	Participants (Count of Participants)
Intervention Arm	264
Placebo Arm	309

The primary outcome of this study is incidence of preterm birth, which will be defined as delivery at or after 20 0/7 weeks and prior to 37 0/7 weeks. This will be determined based on actual date of delivery in comparison to the projected estimated due date (EDD), independent of whether or not the preterm delivery is indicated or spontaneous. (NCT02409680)
Timeframe: At delivery

Incidence of Small for Gestational Age (SGA)

Intervention	Participants (Count of Participants)
Intervention Arm	668
Placebo Arm	754

- Small for gestational age (SGA) as defined by the INTERGROWTH-21st standard (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

Maternal Outcome 1 - Incidence of Vaginal Bleeding

Intervention	Participants (Count of Participants)
Intervention Arm	1506
Placebo Arm	1564

- Vaginal bleeding (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

Maternal Outcome 2 - Incidence of Antepartum Hemorrhage

Intervention	Participants (Count of Participants)
Intervention Arm	214
Placebo Arm	246

- Antepartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

Maternal Outcome 3 - Incidence of Postpartum Hemorrhage

Intervention	Participants (Count of Participants)
Intervention Arm	26
Placebo Arm	25

- Postpartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

Maternal Outcome 4 - Incidence of Maternal Mortality

Intervention	Participants (Count of Participants)
Intervention Arm	54
Placebo Arm	43

- Incidence of Maternal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

Maternal Outcome 5 - Incidence of Late Abortion

Intervention	Participants (Count of Participants)
Intervention Arm	9
Placebo Arm	12

- Incidence of Late Abortion (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

Maternal Outcome 6 - Change in Maternal Hemoglobin

Intervention	Participants (Count of Participants)
Intervention Arm	23
Placebo Arm	30

Hemoglobin < 7.0 gm/dl at 26-30 weeks gestation or a drop of 3.5+ gm/dl from screening to 26-30 weeks gestation (NCT02409680)
Timeframe: At enrollment, 4 weeks post enrollment, and 26-30 weeks GA.

Maternal Outcome 7 - Incidence of Preterm, Preeclampsia

Intervention	Participants (Count of Participants)
Intervention Arm	290
Placebo Arm	333

Early preterm delivery (<34 weeks) and hypertensive disorders (i.e.: preeclampsia) (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

Article	Year
Comparison of non-criteria antiphospholipid syndrome with definite antiphospholipid syndrome: A systematic review. Frontiers in immunology, 2022, Volume: 13 Topics: Antiphospholipid Syndrome; Aspirin; Female; Humans; Pregnancy; Pregnancy Outcome; Thrombosis; Venous	2022
Antiphospholipid syndrome management: a 2023 update and practical algorithm-based approach. Current opinion in rheumatology, 2023, 05-01, Volume: 35, Issue:3 Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Heparin, Low-Molecular-Weight; Humans; P	2023
Does adding hydroxychloroquine to empiric treatment improve the live birth rate in refractory obstetrical antiphospholipid syndrome? A systematic review. American journal of reproductive immunology (New York, N.Y. : 1989), 2023, Volume: 90, Issue:3 Topics: Abortion, Spontaneous; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Birth Rate;	2023
Antiphospholipid syndrome: Diagnosis and management in the obstetric patient. Best practice & research. Clinical obstetrics & gynaecology, 2020, Volume: 64 Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Female; Heparin; Humans; Pregnancy	2020
Comparison of therapeutic interventions for recurrent pregnancy loss in association with antiphospholipid syndrome: A systematic review and network meta-analysis. American journal of reproductive immunology (New York, N.Y. : 1989), 2020, Volume: 83, Issue:4 Topics: Abortion, Spontaneous; Animals; Antiphospholipid Syndrome; Aspirin; Female; Heparin, Low-Molecular-W	2020
Treatment of thrombotic antiphospholipid syndrome in adults and children. Current opinion in rheumatology, 2020, Volume: 32, Issue:3 Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Child; Humans; Prospective Studies; Throm	2020
Understanding and Preventing Placenta-Mediated Pregnancy Complications. Hamostaseologie, 2020, Volume: 40, Issue:3 Topics: Abruptio Placentae; Adult; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome;	2020
Prevention of recurrent miscarriage in women with antiphospholipid syndrome: A systematic review and network meta-analysis. Lupus, 2021, Volume: 30, Issue:1 Topics: Abortion, Habitual; Antiphospholipid Syndrome; Aspirin; Drug Therapy, Combination; Female; Heparin,	2021
The efficacy and safety of second-line treatments of refractory and/or high risk pregnant antiphospholipid syndrome patients. A systematic literature review analyzing 313 pregnancies. Seminars in arthritis and rheumatism, 2021, Volume: 51, Issue:1 Topics: Antiphospholipid Syndrome; Aspirin; Female; Humans; Pregnancy; Pregnancy Complications; Pregnancy Ou	2021
Management of Women with Antiphospholipid Antibodies or Antiphospholipid Syndrome during Pregnancy. Journal of Korean medical science, 2021, Jan-25, Volume: 36, Issue:4 Topics: Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Heparin, L	2021
Meta-analysis on aspirin combined with low-molecular-weight heparin for improving the live birth rate in patients with antiphospholipid syndrome and its correlation with d-dimer levels. Medicine, 2021, Jun-25, Volume: 100, Issue:25 Topics: Abortion, Habitual; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin	2021
Biochemical and clinical predictors in pregnant women with antiphospholipid syndrome and systemic lupus erythematosus: comprehensive update. Archives of gynecology and obstetrics, 2021, Volume: 304, Issue:5 Topics: Adult; Antiphospholipid Syndrome; Aspirin; Female; Heparin, Low-Molecular-Weight; Humans; Infant, Ne	2021
Refractory obstetrical antiphospholipid syndrome: Features, treatment and outcome in a European multicenter retrospective study. Autoimmunity reviews, 2017, Volume: 16, Issue:7 Topics: Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Heparin, L	2017
Primary thromboprophylaxis with low-dose aspirin and antiphospholipid antibodies: Pro's and Con's. Autoimmunity reviews, 2017, Volume: 16, Issue:11 Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; As	2017
Current insights in obstetric antiphospholipid syndrome. Current opinion in obstetrics & gynecology, 2017, Volume: 29, Issue:6 Topics: Abortion, Habitual; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin	2017
Aspirin or heparin or both in the treatment of recurrent spontaneous abortion in women with antiphospholipid antibody syndrome: a meta-analysis of randomized controlled trials. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2019, Volume: 32, Issue:8 Topics: Abortion, Habitual; Adult; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Antiphospholipid	2019
Antiphospholipid syndrome. Nature reviews. Disease primers, 2018, 01-11, Volume: 4 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antiphospholipid; Anticoagulants; Antiph	2018
Obstetric Anti-phospholipid Syndrome: State of the Art. Current rheumatology reports, 2018, 08-13, Volume: 20, Issue:10 Topics: Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Heparin; H	2018
Antiphospholipid syndrome in obstetrics. Lupus, 2018, Volume: 27, Issue:1_suppl Topics: Abortion, Habitual; Adult; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Female;	2018
Management of pregnant women with antiphospholipid antibodies. Expert review of clinical immunology, 2019, Volume: 15, Issue:4 Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Drug Combinations; Female; Heparin	2019
Management of women with recurrent pregnancy losses and antiphospholipid antibody syndrome. American journal of reproductive immunology (New York, N.Y. : 1989), 2013, Volume: 69, Issue:6 Topics: Abortion, Habitual; Animals; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome	2013
Nonsteroidal anti-inflammatory drugs during pregnancy and the initiation of lactation. Anesthesia and analgesia, 2013, Volume: 116, Issue:5 Topics: Abortion, Habitual; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antiphospholipid Syndrome; Aspir	2013
Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. Autoimmunity reviews, 2014, Volume: 13, Issue:3 Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Hemorrhage; Humans; Lupus Erythema	2014
Pregnancy morbidity in antiphospholipid syndrome: what is the impact of treatment? Current rheumatology reports, 2014, Volume: 16, Issue:2 Topics: Abortion, Habitual; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Fetal Growth Retarda	2014
[Serious organ damage and intractable clinical conditions in rheumatic and connective tissue disease--progress in pathophysiology and treatment. Topics: II. Clinical conditions special attention needed to be paid to; 2. Antiphospholipid syndrome]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2013, Oct-10, Volume: 102, Issue:10 Topics: Abortion, Habitual; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin	2013
Antiphospholipid antibody syndrome. Obstetrics and gynecology clinics of North America, 2014, Volume: 41, Issue:1 Topics: Abortion, Habitual; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Female; Fibrin	2014
Antiphospholipid antibody syndrome and reproduction. Current opinion in obstetrics & gynecology, 2014, Volume: 26, Issue:4 Topics: Abortion, Habitual; Antiphospholipid Syndrome; Aspirin; Female; Fibrinolytic Agents; Heparin; Humans	2014
Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia. The Cochrane database of systematic reviews, 2014, Jul-04, Issue:7 Topics: Abortion, Habitual; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Enoxaparin; Female; Heparin,	2014
The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Evidence and clinical judgment. Thrombosis and haemostasis, 2016, Volume: 115, Issue:2 Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Cohort Studies; Female; Heparin; H	2016
Pregnancy and Lupus Nephritis. Seminars in nephrology, 2015, Volume: 35, Issue:5 Topics: Abortion, Spontaneous; Anticoagulants; Antihypertensive Agents; Antiphospholipid Syndrome; Aspirin;	2015
[Antiphospholipid syndrome and pregnancy]. Ugeskrift for laeger, 2016, Jan-18, Volume: 178, Issue:3 Topics: Anticoagulants; Antimalarials; Antiphospholipid Syndrome; Aspirin; Female; Heparin, Low-Molecular-We	2016
Pregnancy in women with systemic lupus erythematosus (SLE). European journal of internal medicine, 2016, Volume: 32 Topics: Abortion, Spontaneous; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspi	2016
Prevention of thrombosis in antiphospholipid syndrome. Hematology. American Society of Hematology. Education Program, 2016, Dec-02, Volume: 2016, Issue:1 Topics: Antiphospholipid Syndrome; Aspirin; Female; Fibrinolytic Agents; Humans; Male; Pregnancy; Pregnancy	2016
Antiphospholipid syndrome. Thrombosis research, 2017, Volume: 151 Suppl 1 Topics: Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Fibrinolyt	2017
[The management of pregnant women with antiphospholipid syndrome]. Polskie Archiwum Medycyny Wewnetrznej, 2007, Volume: 117 Suppl Topics: Abortion, Habitual; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Fibrinolytic Agents;	2007
[Pregnancy and antiphospholipid antibodies]. Presse medicale (Paris, France : 1983), 2008, Volume: 37, Issue:11 Topics: Animals; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Complemen	2008
Update on antiphospholipid syndrome. Bulletin of the NYU hospital for joint diseases, 2008, Volume: 66, Issue:3 Topics: Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Blood Coagulation;	2008
[Ischemic stroke with antiphospholipid antibody]. Brain and nerve = Shinkei kenkyu no shinpo, 2008, Volume: 60, Issue:10 Topics: Age of Onset; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Biom	2008
Aspirin or anticoagulants for treating recurrent miscarriage in women without antiphospholipid syndrome. The Cochrane database of systematic reviews, 2009, Jan-21, Issue:1 Topics: Abortion, Habitual; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Heparin, Low-Molecul	2009
Thromboprophylaxis and obstetric management of the antiphospholipid syndrome. Expert opinion on pharmacotherapy, 2009, Volume: 10, Issue:4 Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Catastrophic Illness; Drug Therapy, Combi	2009
[The antiphospholipid syndrome in the 21st century]. Medicina clinica, 2009, Sep-19, Volume: 133, Issue:10 Topics: Adult; Antibodies, Anticardiolipin; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Clinical Tri	2009
Recurrent miscarriage. BMJ clinical evidence, 2008, Apr-14, Volume: 2008 Topics: Abortion, Habitual; Anti-Inflammatory Agents, Non-Steroidal; Antiphospholipid Syndrome; Aspirin; Hep	2008
Management of antiphospholipid syndrome. Journal of autoimmunity, 2009, Volume: 33, Issue:2 Topics: Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Fibrinolyt	2009
[Management of antiphospholipid syndrome]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2009, Volume: 50, Issue:10 Topics: Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Biomarkers; Enzyme	2009
Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression. Rheumatology (Oxford, England), 2010, Volume: 49, Issue:2 Topics: Abortion, Habitual; Adult; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome;	2010
Antiphospholipid antibody syndrome. Hematology. American Society of Hematology. Education Program, 2009 Topics: Abortion, Habitual; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Blood Transfus	2009
Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: a systematic review and meta-analysis. Obstetrics and gynecology, 2010, Volume: 115, Issue:6 Topics: Abortion, Habitual; Antiphospholipid Syndrome; Aspirin; Drug Therapy, Combination; Female; Fibrinoly	2010
Primary thrombosis prophylaxis in antiphospholipid antibody-positive patients: where do we stand? Current rheumatology reports, 2011, Volume: 13, Issue:1 Topics: Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Humans; Ma	2011
Heparin or aspirin or both in the treatment of recurrent abortions in women with antiphospholipid antibody (syndrome). Current opinion in rheumatology, 2011, Volume: 23, Issue:3 Topics: Abortion, Habitual; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Clinical Trials as Topic; Dr	2011
Recurrent miscarriage. BMJ clinical evidence, 2011, Feb-01, Volume: 2011 Topics: Abortion, Habitual; Anti-Inflammatory Agents, Non-Steroidal; Antiphospholipid Syndrome; Aspirin; Hep	2011
Obstetric antiphospholipid syndrome. Autoimmunity reviews, 2012, Volume: 11, Issue:4 Topics: Abortion, Habitual; Animals; Antibodies, Antiphospholipid; Antibody-Dependent Cell Cytotoxicity; Ant	2012
Obstetric antiphospholipid syndrome: an update on pathophysiology and management. Seminars in reproductive medicine, 2011, Volume: 29, Issue:6 Topics: Abortion, Habitual; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Female; Hepari	2011
[Management of antiphospholipid syndrome]. La Revue de medecine interne, 2012, Volume: 33, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; As	2012
Novel insights into pathogenesis, diagnosis and treatment of antiphospholipid syndrome. Current opinion in rheumatology, 2012, Volume: 24, Issue:5 Topics: Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; beta 2-Glycoprotei	2012
Recurrent miscarriage and thrombophilia: an update. Current opinion in obstetrics & gynecology, 2012, Volume: 24, Issue:4 Topics: Abortion, Habitual; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Evidence-Based Medicine; Fem	2012
[Antiphospholipid-syndrome - when to treat?]. Deutsche medizinische Wochenschrift (1946), 2012, Volume: 137, Issue:36 Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; As	2012
Antiphospholipid antibody syndrome. Current opinion in ophthalmology, 2012, Volume: 23, Issue:6 Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; beta 2-Glycoprotein I; Humans; Hyd	2012
[Medical treatment for recurrent miscarriages]. Gynecologie, obstetrique & fertilite, 2002, Volume: 30, Issue:6 Topics: Abortion, Habitual; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulant	2002
Treatment and monitoring of patients with antiphospholipid antibodies and thrombotic history (Hughes syndrome). Current rheumatology reports, 2002, Volume: 4, Issue:5 Topics: Acute Disease; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Drug Monitoring; Heparin, Low-Mol	2002
Prevention of thrombosis during pregnancy. The Israel Medical Association journal : IMAJ, 2002, Volume: 4, Issue:10 Topics: Administration, Oral; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Blood Coagulation Tests; B	2002
[Antiphospholipid syndrome]. Annales de cardiologie et d'angeiologie, 2002, Volume: 51, Issue:3 Topics: Adult; Aged; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Femal	2002
Low molecular weight heparin in immunological recurrent abortion--the incredible cure. Journal of assisted reproduction and genetics, 2003, Volume: 20, Issue:2 Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Anticoagulants; Antiphospholipid Syndrome; Aspirin;	2003
Antiphospholipid syndrome in obstetrics. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2003, Volume: 9, Issue:2 Topics: Abortion, Habitual; Abortion, Spontaneous; Adult; Annexin A5; Antibodies, Anticardiolipin; Anticoagu	2003
Treatment of pregnancy loss in Hughes syndrome: a critical update. Autoimmunity reviews, 2002, Volume: 1, Issue:5 Topics: Abortion, Habitual; Antiphospholipid Syndrome; Aspirin; Clinical Trials as Topic; Female; Heparin; H	2002
Antibody-mediated thrombosis and pregnancy loss. The Nurse practitioner, 2003, Volume: 28, Issue:7 Pt 1 Topics: Abortion, Spontaneous; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Drug Therapy, Combination	2003
Prophylaxis of the antiphospholipid syndrome: a consensus report. Lupus, 2003, Volume: 12, Issue:7 Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Humans; Lupus Erythematosus, Systemic; P	2003
Evidence-based management of thrombosis in the antiphospholipid antibody syndrome. Current rheumatology reports, 2003, Volume: 5, Issue:5 Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Evidence-Based Medicine; Humans; International N	2003
[Indications for anticoagulant use in secondary prevention of strokes]. Presse medicale (Paris, France : 1983), 2003, Jul-26, Volume: 32, Issue:25 Topics: Anticoagulants; Antiphospholipid Syndrome; Arteriosclerosis; Aspirin; Atrial Fibrillation; Cardiovas	2003
[Treatment of recurrent spontaneous abortion associated with the antiphospholipid antibody syndrome]. Gynecologie, obstetrique & fertilite, 2003, Volume: 31, Issue:9 Topics: Abortion, Habitual; Adrenal Cortex Hormones; Antiphospholipid Syndrome; Aspirin; Female; Heparin; Hu	2003
Recurrent spontaneous early pregnancy loss and low dose aspirin. Minerva ginecologica, 2003, Volume: 55, Issue:5 Topics: Abortion, Habitual; Antiphospholipid Syndrome; Aspirin; Clinical Trials as Topic; Female; Humans; Pl	2003
Review of severe vaso-occlusive retinopathy in systemic lupus erythematosus and the antiphospholipid syndrome: associations, visual outcomes, complications and treatment. Clinical & experimental ophthalmology, 2004, Volume: 32, Issue:1 Topics: Adult; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Combined Mo	2004
Antiphospholipid syndrome and second- or third-trimester fetal death: follow-up in the next pregnancy. European journal of obstetrics, gynecology, and reproductive biology, 2004, Jun-15, Volume: 114, Issue:2 Topics: Adult; Antibodies, Anticardiolipin; Antiphospholipid Syndrome; Arteries; Aspirin; Female; Fetal Deat	2004
Evidence-based treatment of the antiphospholipid syndrome: I. Pregnancy failure. Thrombosis research, 2004, Volume: 114, Issue:2 Topics: Abortion, Habitual; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Clinical Trials as Topic; Ev	2004
The management of pregnant patients with antiphospholipid syndrome. Lupus, 2004, Volume: 13, Issue:9 Topics: Abortion, Habitual; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Heparin; Humans; Pla	2004
Treatment of antiphospholipid syndrome in pregnancy--a systematic review of randomized therapeutic trials. Thrombosis research, 2004, Volume: 114, Issue:5-6 Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Clinical Trials as Topic; Female;	2004
Immunologic manipulation for the threatened fetus. Thrombosis research, 2004, Volume: 114, Issue:5-6 Topics: Abortion, Habitual; Antiphospholipid Syndrome; Aspirin; B-Lymphocytes; Complement C1 Inactivator Pro	2004
Evidence based treatment of the antiphospholipid syndrome II. Optimal anticoagulant therapy for thrombosis. Thrombosis research, 2005, Volume: 115, Issue:1-2 Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Clinical Trials as Topic; Evidence-Based Medicin	2005
Systemic lupus erythematosus with simultaneous onset of Kikuchi-Fujimoto's disease complicated with antiphospholipid antibody syndrome: a case report and review of the literature. Rheumatology international, 2005, Volume: 25, Issue:4 Topics: Administration, Oral; Adult; Anti-Inflammatory Agents; Anticoagulants; Antiphospholipid Syndrome; An	2005
[Thrombophilias and vascular placental pathology. A survey of the literature]. La Revue de medecine interne, 2005, Volume: 26, Issue:2 Topics: Activated Protein C Resistance; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Cohort Studies;	2005
Anticoagulation therapy in the antiphospholipid syndrome: recent advances. Current opinion in pulmonary medicine, 2005, Volume: 11, Issue:5 Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Humans; Kidney Transplantation; Pregnanc	2005
Antiphospholipid antibodies in young adults with stroke. Journal of thrombosis and thrombolysis, 2005, Volume: 20, Issue:2 Topics: Adolescent; Adult; Age Factors; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagu	2005
Obstetrical antiphospholipid syndrome. Seminars in reproductive medicine, 2006, Volume: 24, Issue:1 Topics: Abortion, Habitual; Anti-Inflammatory Agents, Non-Steroidal; Antiphospholipid Syndrome; Aspirin; Fem	2006
[Systematic lupus erythematosus and antiphospholipid syndrome during pregnancy]. Zeitschrift fur Rheumatologie, 2006, Volume: 65, Issue:3 Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Disease Progression; Female; Humans; Immunosuppr	2006
[Antiphospholipid syndrome]. No to shinkei = Brain and nerve, 2006, Volume: 58, Issue:11 Topics: Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Blood Coagulation	2006
[Newborn from mother with antiphospholipid syndrome]. Polskie Archiwum Medycyny Wewnetrznej, 2006, Volume: 115, Issue:5 Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; beta 2-Glycoprotein I; Female; Fet	2006
[Fetus monitoring of a mother suffering from the antiphospholipid syndrome]. Polskie Archiwum Medycyny Wewnetrznej, 2006, Volume: 115, Issue:5 Topics: Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Biomarkers; Female	2006
The obstetric antiphospholipid syndrome. Journal of reproductive immunology, 2008, Volume: 77, Issue:1 Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antiphospholipid Syndrome; Aspirin; Female; Heparin	2008
[The antiphospholipid syndrome, an update]. Anales de medicina interna (Madrid, Spain : 1984), 2007, Volume: 24, Issue:5 Topics: Abortion, Spontaneous; Acenocoumarol; Adult; Antibodies, Anticardiolipin; Anticoagulants; Antiphosph	2007
Insights into atherosclerosis therapy in antiphospholipid syndrome. Autoimmunity reviews, 2007, Volume: 7, Issue:1 Topics: Adrenal Cortex Hormones; Animals; Anti-Inflammatory Agents; Antibodies, Antiphospholipid; Antiphosph	2007
Non-surgical interventions for threatened and recurrent miscarriages. Singapore medical journal, 2007, Volume: 48, Issue:12 Topics: Abortion, Habitual; Abortion, Threatened; Antiphospholipid Syndrome; Aspirin; Bed Rest; Chorionic Go	2007
A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis and rheumatism, 2007, Dec-15, Volume: 57, Issue:8 Topics: Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Humans; Internatio	2007
Antiphospholipid syndrome in pregnancy. Hematology/oncology clinics of North America, 2008, Volume: 22, Issue:1 Topics: Abortion, Habitual; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin	2008
Evaluation of the obstetrical risks of the antiphospholipid syndrome and therapeutic management. Clinical reviews in allergy & immunology, 1995,Spring, Volume: 13, Issue:1 Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Female; Glucocorticoids; Heparin;	1995
Understanding prostaglandin metabolites and platelet-activating factor in the pathophysiology and treatment of the antiphospholipid syndrome. Clinics in perinatology, 1995, Volume: 22, Issue:2 Topics: Abortion, Habitual; Antiphospholipid Syndrome; Aspirin; Female; Humans; Platelet Activating Factor;	1995
Antiphospholipid syndrome: from the laboratory bench to the patients' bedside. Lupus, 1995, Volume: 4 Suppl 1 Topics: Animals; Antiphospholipid Syndrome; Aspirin; Disease Models, Animal; Drug Therapy, Combination; Fema	1995
Role of IL-3 in the antiphospholipid syndrome. Lupus, 1994, Volume: 3, Issue:4 Topics: Animals; Antiphospholipid Syndrome; Aspirin; Humans; Interleukin-3	1994
Immunosuppression of experimental systemic lupus erythematosus and antiphospholipid syndrome. Transplantation proceedings, 1994, Volume: 26, Issue:6 Topics: Adjuvants, Immunologic; Androgens; Animals; Antibodies, Anti-Idiotypic; Antiphospholipid Syndrome; A	1994
Cardiac manifestations of the antiphospholipid syndrome. Coronary artery disease, 1993, Volume: 4, Issue:12 Topics: Antibodies, Anticardiolipin; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Coronary Disease; H	1993
[Therapeutic management of antiphospholipid antibody syndrome in pregnancy]. Contraception, fertilite, sexualite (1992), 1993, Volume: 21, Issue:11 Topics: Adrenal Cortex Hormones; Antiphospholipid Syndrome; Aspirin; Female; Heparin; Humans; Pregnancy; Pre	1993
[Antiphospholipid syndrome. Proposition for management]. Journal de gynecologie, obstetrique et biologie de la reproduction, 1993, Volume: 22, Issue:3 Topics: Antiphospholipid Syndrome; Aspirin; Female; Heparin; Humans; Immunoglobulins, Intravenous; Mass Scre	1993
Prevention of fetal death in the antiphospholipid antibody syndrome. Lupus, 1996, Volume: 5, Issue:5 Topics: Adrenal Cortex Hormones; Animals; Antiphospholipid Syndrome; Aspirin; Female; Fetal Death; Heparin;	1996
[Diagnosis and therapy of antiphospholipid antibody syndrome]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1998, Mar-10, Volume: 87, Issue:3 Topics: Anti-Inflammatory Agents; Antibodies, Anticardiolipin; Anticoagulants; Antiphospholipid Syndrome; As	1998
ACOG educational bulletin. Antiphospholipid syndrome. Number 244, February 1998. American College of Obstetricians and Gynecologists. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 1998, Volume: 61, Issue:2 Topics: Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Heparin; H	1998
The antiphospholipid antibody syndrome. Australian family physician, 1998, Volume: 27, Issue:8 Topics: Abortion, Habitual; Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Heparin; Huma	1998
Treatment of the antiphospholipid syndrome in pregnancy. Scandinavian journal of rheumatology. Supplement, 1998, Volume: 107 Topics: Abortion, Spontaneous; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Anticoagula	1998
Antiphospholipid antibodies and infertility: fact or fallacy. Lupus, 1998, Volume: 7 Suppl 2 Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Antip	1998
Management of thrombosis and pregnancy loss in the antiphospholipid syndrome. Lupus, 1998, Volume: 7 Suppl 2 Topics: Abortion, Habitual; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin	1998
[Current obstetrical management of antiphospholipid antibody syndrome: review of the literature apropos of 20 cases]. Contraception, fertilite, sexualite (1992), 1998, Volume: 26, Issue:9 Topics: Abortion, Spontaneous; Adrenal Cortex Hormones; Anticoagulants; Antiphospholipid Syndrome; Aspirin;	1998
Antiphospholipid syndrome and pregnancy loss. Hospital medicine (London, England : 1998), 1998, Volume: 59, Issue:8 Topics: Abortion, Habitual; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Antiphospholipid Syndro	1998
Chorea as the presenting clinical feature of primary antiphospholipid syndrome in childhood. Neuropediatrics, 1999, Volume: 30, Issue:2 Topics: Adolescent; Adrenal Cortex Hormones; Antibodies, Anticardiolipin; Antibodies, Antinuclear; Antiphosp	1999
[Aspirin and antiphospholipid syndrome]. La Revue de medecine interne, 2000, Volume: 21 Suppl 1 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Antiphospholipid Syndrome; Arteriosc	2000
[Antiphospholipid antibody syndrome in adverse pregnancy]. Rinsho byori. The Japanese journal of clinical pathology, 2000, Volume: 48, Issue:4 Topics: Abortion, Habitual; Abortion, Spontaneous; Antibodies, Anticardiolipin; Antiphospholipid Syndrome; A	2000
Intravenous immunoglobulin therapy of antiphospholipid syndrome. Rheumatology (Oxford, England), 2000, Volume: 39, Issue:4 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antiphospholipid; Anticoagulants; Antiph	2000
[Diagnosis and management for antiphospholipid syndrome]. Rinsho byori. The Japanese journal of clinical pathology, 2000, Volume: 48, Issue:5 Topics: Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Biomarkers; Female	2000
[Therapeutic use of intravenous immunoglobulins in the antiphospholipid syndrome]. Annales de medecine interne, 2000, Volume: 151 Suppl 1 Topics: Abortion, Habitual; Abortion, Spontaneous; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Femal	2000
Recurrent miscarriage syndrome and infertility caused by blood coagulation protein or platelet defects. Hematology/oncology clinics of North America, 2000, Volume: 14, Issue:5 Topics: Abortion, Habitual; Adult; Antiphospholipid Syndrome; Aspirin; Blood Platelet Disorders; Coagulation	2000
Treatment of the antiphospholipid antibody syndrome: progress in the last five years? Current rheumatology reports, 2000, Volume: 2, Issue:3 Topics: Abortion, Spontaneous; Antiphospholipid Syndrome; Aspirin; B-Lymphocytes; Hematopoietic Stem Cell Tr	2000
Antiphospholipid syndrome and recurrent miscarriages. European journal of obstetrics, gynecology, and reproductive biology, 2001, Volume: 96, Issue:1 Topics: Abortion, Habitual; Adrenal Cortex Hormones; Antibodies, Anticardiolipin; Antibodies, Antiphospholip	2001
Update on the management of the pregnant patient with antiphospholipid antibody. Current rheumatology reports, 2001, Volume: 3, Issue:3 Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Humans; Pregnancy; Pregnancy Complicatio	2001
A literature review on the antiphospholipid syndrome and the effect on childbearing. Midwifery, 2001, Volume: 17, Issue:2 Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Embolism; Female; Fetal Death; Fetal Diseases; F	2001
The epidemiology of the antiphospholipid syndrome: who is at risk? Current rheumatology reports, 2001, Volume: 3, Issue:4 Topics: Adolescent; Adult; Age Factors; Aged; Animals; Antibodies, Anticardiolipin; Antibodies, Antiphosphol	2001
Management of thrombosis in antiphospholipid antibody syndrome. Rheumatic diseases clinics of North America, 2001, Volume: 27, Issue:3 Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Hemorrhage; Heparin; Humans; Lupus Erythematosus	2001
Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of therapeutic trials. Obstetrics and gynecology, 2002, Volume: 99, Issue:1 Topics: Abortion, Habitual; Adult; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Drug Th	2002
Treatment of the antiphospholipid syndrome. Current opinion in rheumatology, 2002, Volume: 14, Issue:3 Topics: Abortion, Spontaneous; Antiphospholipid Syndrome; Aspirin; Female; Fibrinolytic Agents; Humans; Nerv	2002
Autoimmune factors in assisted reproduction. Minerva ginecologica, 2002, Volume: 54, Issue:3 Topics: Abortion, Habitual; Abortion, Spontaneous; Adrenal Cortex Hormones; Antibodies, Anticardiolipin; Ant	2002
Use of antithrombotic agents during pregnancy. Chest, 1992, Volume: 102, Issue:4 Suppl Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Fetal Diseases; Hemorrhage; Humans; Oste	1992

Article	Year
Heparin and aspirin combination therapy restores T-cell phenotype in pregnant patients with antiphospholipid syndrome-related recurrent pregnancy loss. Clinical immunology (Orlando, Fla.), 2019, Volume: 208 Topics: Abortion, Habitual; Adult; Antiphospholipid Syndrome; Aspirin; Drug Therapy, Combination; Female; Fi	2019
Use of D-dimer measurement to guide anticoagulant treatment in recurrent pregnancy loss associated with antiphospholipid syndrome. American journal of reproductive immunology (New York, N.Y. : 1989), 2017, Volume: 78, Issue:6 Topics: Abortion, Habitual; Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Drug Therapy, Combina	2017
Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS). Rheumatology (Oxford, England), 2014, Volume: 53, Issue:2 Topics: Adult; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Autoimmune	2014
Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. European journal of obstetrics, gynecology, and reproductive biology, 2016, Volume: 197 Topics: Adult; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Australia; Drug Therapy, Co	2016
Randomized controlled study of pre-conception thromboprophylaxis among patients with recurrent spontaneous abortion related to antiphospholipid syndrome. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2016, Volume: 132, Issue:2 Topics: Abortion, Habitual; Adult; Antiphospholipid Syndrome; Aspirin; Drug Therapy, Combination; Egypt; Eno	2016
Obstetric antiphospholipid syndrome: early variations of angiogenic factors are associated with adverse outcomes. Haematologica, 2017, Volume: 102, Issue:5 Topics: Adolescent; Adult; Antiphospholipid Syndrome; Aspirin; Female; Fibrinolytic Agents; Heparin, Low-Mol	2017
Low-molecular-weight heparin versus intravenous immunoglobulin for recurrent abortion associated with antiphospholipid antibody syndrome. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2009, Volume: 104, Issue:3 Topics: Abortion, Habitual; Adolescent; Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Dose-Resp	2009
Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. The Journal of rheumatology, 2009, Volume: 36, Issue:2 Topics: Abortion, Habitual; Adult; Antibodies, Antinuclear; Anticoagulants; Antiphospholipid Syndrome; Aspir	2009
Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome. International journal of medical sciences, 2009, Dec-05, Volume: 7, Issue:1 Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Drug Therapy, Combination; Female; Humans; Kapla	2009
[Recurrent thromboses and hemorrhagic complications in patients with antiphospholipid syndrome during therapy with warfarin plus aspirin]. Terapevticheskii arkhiv, 2010, Volume: 82, Issue:5 Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Aryl Hydrocarbon Hydroxylases; Aspirin; Blood Coag	2010
Heparin and aspirin in pregnant Sudanese women with recurrent miscarriage associated with antiphospholipid antibodies. African journal of reproductive health, 2007, Volume: 11, Issue:2 Topics: Abortion, Habitual; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin	2007
Enoxaparin versus unfractionated heparin in the management of recurrent abortion secondary to antiphospholipid syndrome. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2011, Volume: 112, Issue:3 Topics: Abortion, Habitual; Adult; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome;	2011
Bemiparin versus low dose aspirin for management of recurrent early pregnancy losses due to antiphospholipd antibody syndrome. Archives of gynecology and obstetrics, 2012, Volume: 285, Issue:3 Topics: Abortion, Habitual; Adult; Antiphospholipid Syndrome; Aspirin; Embryo Loss; Female; Heparin, Low-Mol	2012
Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstetrics and gynecology, 2002, Volume: 100, Issue:3 Topics: Abortion, Spontaneous; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Confidence	2002
Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstetrics and gynecology, 2002, Volume: 100, Issue:6 Topics: Antiphospholipid Syndrome; Aspirin; Double-Blind Method; Drug Therapy, Combination; Female; Gestatio	2002
Antiphospholipid syndrome in pregnancy. Obstetrics and gynecology, 2002, Volume: 100, Issue:6 Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Double-Blind Method; Female; Gestational Age; He	2002
Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. Arthritis and rheumatism, 2003, Volume: 48, Issue:3 Topics: Abortion, Habitual; Adolescent; Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Drug Ther	2003
[Treatment outcome in women suffering from recurrent miscarriages and antiphospholipid syndrome]. Ginekologia polska, 2003, Volume: 74, Issue:10 Topics: Abortion, Habitual; Adult; Antibodies, Anticardiolipin; Anticoagulants; Antiphospholipid Syndrome; A	2003
Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin. Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 2004, Volume: 26, Issue:8 Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Dalteparin; Female; Heparin; Humans; Pilo	2004
Treatment of antiphospholipid syndrome in pregnancy--a systematic review of randomized therapeutic trials. Thrombosis research, 2004, Volume: 114, Issue:5-6 Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Clinical Trials as Topic; Female;	2004
Recurrent miscarriage associated with antiphospholipid antibodies: prophylactic treatment with low-dose aspirin and fish oil derivates. Clinical and experimental obstetrics & gynecology, 2005, Volume: 32, Issue:1 Topics: Abortion, Habitual; Adult; Antiphospholipid Syndrome; Aspirin; Docosahexaenoic Acids; Dose-Response	2005
A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). Journal of thrombosis and haemostasis : JTH, 2005, Volume: 3, Issue:5 Topics: Administration, Oral; Adult; Algorithms; Antibodies, Anticardiolipin; Anticoagulants; Antiphospholip	2005
Comparison of two therapeutic protocols in patients with antiphospholipid antibodies and recurrent miscarriages. Vojnosanitetski pregled, 2005, Volume: 62, Issue:6 Topics: Abortion, Habitual; Adult; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Drug Th	2005
Aspirin desensitization in the treatment of antiphospholipid syndrome during pregnancy in ASA-sensitive patients. American journal of reproductive immunology (New York, N.Y. : 1989), 2006, Volume: 55, Issue:1 Topics: Adult; Antiphospholipid Syndrome; Aspirin; Desensitization, Immunologic; Female; Fetal Death; Follow	2006
Preliminary prospective study of the endocrinology of conception cycles and early pregnancy in women with antiphospholipid syndrome treated with low molecular weight heparin. Fertility and sterility, 2006, Volume: 85, Issue:1 Topics: Abortion, Habitual; Activins; Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Case-Contro	2006
Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis and rheumatism, 2007, Volume: 56, Issue:7 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antiphospholipid Syndrome; Aspirin; Double-Blind Met	2007
[Warfarin in the treatment of antiphospholipid syndrome]. Terapevticheskii arkhiv, 2007, Volume: 79, Issue:5 Topics: Anticoagulants; Antiphospholipid Syndrome; Aryl Hydrocarbon Hydroxylases; Aspirin; Blood Coagulation	2007
Thrombosis and antiphospholipid syndrome: a preliminary assessment of three antithrombotic treatments. Lupus, 1994, Volume: 3, Issue:2 Topics: Adolescent; Adult; Antibodies, Anticardiolipin; Anticoagulants; Antiphospholipid Syndrome; Aspirin;	1994
Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients. American journal of obstetrics and gynecology, 1993, Volume: 169, Issue:6 Topics: Adult; Antibodies, Anticardiolipin; Antiphospholipid Syndrome; Aspirin; Drug Therapy, Combination; F	1993
[Antiphospholipid antibodies in women with habitual abortions. Treatment with prednisone and acetylsalicylic acid during pregnancy]. Sangre, 1995, Volume: 40, Issue:5 Topics: Abortion, Habitual; Adult; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Drug Th	1995
Randomized trial of aspirin versus aspirin and heparin in pregnant women with the antiphospholipid syndrome. Annales de medecine interne, 1996, Volume: 147 Suppl 1 Topics: Adult; Antiphospholipid Syndrome; Aspirin; Dose-Response Relationship, Drug; Drug Therapy, Combinati	1996
Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies) BMJ (Clinical research ed.), 1997, Jan-25, Volume: 314, Issue:7076 Topics: Abortion, Habitual; Adult; Antibodies, Anticardiolipin; Antiphospholipid Syndrome; Aspirin; Female;	1997
Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. American journal of obstetrics and gynecology, 1996, Volume: 174, Issue:5 Topics: Abortion, Habitual; Adult; Antiphospholipid Syndrome; Aspirin; Drug Therapy, Combination; Female; He	1996
Do low-risk pregnant women with antiphospholipid antibodies need to be treated? Organizing Group of the Antiphospholipid Antibody Treatment Trial. American journal of obstetrics and gynecology, 1997, Volume: 176, Issue:5 Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Female; Humans; Pregnancy; Pregnan	1997
The selective use of heparin/aspirin therapy, alone or in combination with intravenous immunoglobulin G, in the management of antiphospholipid antibody-positive women undergoing in vitro fertilization. American journal of reproductive immunology (New York, N.Y. : 1989), 1998, Volume: 40, Issue:2 Topics: Abortion, Habitual; Adult; Antiphospholipid Syndrome; Aspirin; Case-Control Studies; Drug Therapy, C	1998
Pregnancy complications in women with recurrent miscarriage associated with antiphospholipid antibodies treated with low dose aspirin and heparin. British journal of obstetrics and gynaecology, 1999, Volume: 106, Issue:2 Topics: Abortion, Habitual; Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Cesarean Section; Dru	1999
Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial. American journal of obstetrics and gynecology, 2000, Volume: 183, Issue:4 Topics: Adult; Antiphospholipid Syndrome; Aspirin; Double-Blind Method; Female; Humans; Pregnancy; Pregnancy	2000
Appropriate management of antiphospholipid-related pregnancy in women without lupus who have low titer autoantibodies. Current rheumatology reports, 2001, Volume: 3, Issue:4 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antiphospholipid; Antiphospholipid Syndr	2001
Low molecular weight heparin and warfarin in the treatment of patients with antiphospholipid syndrome during pregnancy. Thrombosis and haemostasis, 2001, Volume: 86, Issue:6 Topics: Abnormalities, Drug-Induced; Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Autoimmune D	2001
Enoxaparin sodium improves pregnancy outcome in aspirin-resistant antiphospholipid/antiprotein antibody syndromes. Thrombosis and haemostasis, 2002, Volume: 87, Issue:3 Topics: Abortion, Habitual; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Drug Resistance; Enoxaparin;	2002
Effectiveness of prednisolone/aspirin therapy for recurrent aborters with antiphospholipid antibody. Human reproduction (Oxford, England), 1992, Volume: 7, Issue:2 Topics: Abortion, Habitual; Adult; Antibodies; Antiphospholipid Syndrome; Aspirin; Cardiolipins; Drug Evalua	1992

aspirin and Antiphospholipid Syndrome